Understanding the immunogenicity and antigenicity of nanomaterials: Past, present and future
Nanoparticle immunogenicity and antigenicity have been under investigation for many years. During the past decade, significant progress has been made in understanding what makes a nanoparticle immunogenic, how immune cells respond to nanoparticles, what consequences of nanoparticle-specific antibody...
Saved in:
| Published in | Toxicology and applied pharmacology Vol. 299; pp. 70 - 77 |
|---|---|
| Main Authors | , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Elsevier Inc
15.05.2016
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Nanoparticle immunogenicity and antigenicity have been under investigation for many years. During the past decade, significant progress has been made in understanding what makes a nanoparticle immunogenic, how immune cells respond to nanoparticles, what consequences of nanoparticle-specific antibody formation exist and how they challenge the application of nanoparticles for drug delivery. Moreover, it has been recognized that accidental contamination of therapeutic protein formulations with nanosized particulate materials may contribute to the immunogenicity of this type of biotechnology products. While the immunological properties of engineered nanomaterials and their application as vaccine carriers and adjuvants have been given substantial consideration in the current literature, little attention has been paid to nanoparticle immuno- and antigenicity. To fill in this gap, we herein provide an overview of this subject to highlight the current state of the field, review past and present research, and discuss future research directions.
[Display omitted]
•Most engineered nanomaterials are not immunogenic per se.•Generation of nanoparticle-specific antibody can be T-cell dependent or independent.•Antibodies can be generated to particle core, terminal groups or surface coatings.•Engineered and accidental nanomaterials have distinct contribution to immunogenicity.•Tunable physicochemical properties make each nanoparticle unique. |
|---|---|
| AbstractList | Nanoparticle immunogenicity and antigenicity have been under investigation for many years. During the past decade, significant progress has been made in understanding what makes a nanoparticle immunogenic, how immune cells respond to nanoparticles, what consequences of nanoparticle-specific antibody formation exist and how they challenge the application of nanoparticles for drug delivery. Moreover, it has been recognized that accidental contamination of therapeutic protein formulations with nanosized particulate materials may contribute to the immunogenicity of this type of biotechnology products. While the immunological properties of engineered nanomaterials and their application as vaccine carriers and adjuvants have been given substantial consideration in the current literature, little attention has been paid to nanoparticle immuno- and antigenicity. To fill in this gap, we herein provide an overview of this subject to highlight the current state of the field, review past and present research, and discuss future research directions. Nanoparticle immunogenicity and antigenicity have been under investigation for many years. During the past decade, significant progress has been made in understanding what makes a nanoparticle immunogenic, how immune cells respond to nanoparticles, what consequences of nanoparticle-specific antibody formation exist and how they challenge the application of nanoparticles for drug delivery. Moreover, it has been recognized that accidental contamination of therapeutic protein formulations with nanosized particulate materials may contribute to the immunogenicity of this type of biotechnology products. While the immunological properties of engineered nanomaterials and their application as vaccine carriers and adjuvants have been given substantial consideration in the current literature, little attention has been paid to nanoparticle immuno- and antigenicity. To fill in this gap, we herein provide an overview of this subject to highlight the current state of the field, review past and present research, and discuss future research directions. - Highlights: • Most engineered nanomaterials are not immunogenic per se. • Generation of nanoparticle-specific antibody can be T-cell dependent or independent. • Antibodies can be generated to particle core, terminal groups or surface coatings. • Engineered and accidental nanomaterials have distinct contribution to immunogenicity. • Tunable physicochemical properties make each nanoparticle unique. Nanoparticle immunogenicity and antigenicity have been under investigation for many years. During the past decade, significant progress has been made in understanding what makes a nanoparticle immunogenic, how immune cells respond to nanoparticles, what consequences of nanoparticle-specific antibody formation exist and how they challenge the application of nanoparticles for drug delivery. Moreover, it has been recognized that accidental contamination of therapeutic protein formulations with nanosized particulate materials may contribute to the immunogenicity of this type of biotechnology products. While the immunological properties of engineered nanomaterials and their application as vaccine carriers and adjuvants have been given substantial consideration in the current literature, little attention has been paid to nanoparticle immuno- and antigenicity. To fill in this gap, we herein provide an overview of this subject to highlight the current state of the field, review past and present research, and discuss future research directions.Nanoparticle immunogenicity and antigenicity have been under investigation for many years. During the past decade, significant progress has been made in understanding what makes a nanoparticle immunogenic, how immune cells respond to nanoparticles, what consequences of nanoparticle-specific antibody formation exist and how they challenge the application of nanoparticles for drug delivery. Moreover, it has been recognized that accidental contamination of therapeutic protein formulations with nanosized particulate materials may contribute to the immunogenicity of this type of biotechnology products. While the immunological properties of engineered nanomaterials and their application as vaccine carriers and adjuvants have been given substantial consideration in the current literature, little attention has been paid to nanoparticle immuno- and antigenicity. To fill in this gap, we herein provide an overview of this subject to highlight the current state of the field, review past and present research, and discuss future research directions. Nanoparticle immunogenicity and antigenicity have been under investigation for many years. During the past decade, significant progress has been made in understanding what makes a nanoparticle immunogenic, how immune cells respond to nanoparticles, what consequences of nanoparticle-specific antibody formation exist and how they challenge the application of nanoparticles for drug delivery. Moreover, it has been recognized that accidental contamination of therapeutic protein formulations with nanosized particulate materials may contribute to the immunogenicity of this type of biotechnology products. While the immunological properties of engineered nanomaterials and their application as vaccine carriers and adjuvants have been given substantial consideration in the current literature, little attention has been paid to nanoparticle immuno- and antigenicity. To fill in this gap, we herein provide an overview of this subject to highlight the current state of the field, review past and present research, and discuss future research directions. [Display omitted] •Most engineered nanomaterials are not immunogenic per se.•Generation of nanoparticle-specific antibody can be T-cell dependent or independent.•Antibodies can be generated to particle core, terminal groups or surface coatings.•Engineered and accidental nanomaterials have distinct contribution to immunogenicity.•Tunable physicochemical properties make each nanoparticle unique. |
| Author | Ilinskaya, Anna N. Dobrovolskaia, Marina A. |
| Author_xml | – sequence: 1 givenname: Anna N. surname: Ilinskaya fullname: Ilinskaya, Anna N. – sequence: 2 givenname: Marina A. surname: Dobrovolskaia fullname: Dobrovolskaia, Marina A. email: marina@mail.nih.gov |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26773813$$D View this record in MEDLINE/PubMed https://www.osti.gov/biblio/22689167$$D View this record in Osti.gov |
| BookMark | eNqNUk2LFDEQDbLizq7-AQ_S4MWD3eazkxYRZPELFvTgggchZNLVMxm6k9kkvbD_3rSzDuph8RASUu9Vvap6Z-jEBw8IPSW4IZi0r3ZNNmbf0PJuMGkwFg_QiuCurTFj7AStMOakxlh9P0VnKe0wxh3n5BE6pa2UTBG2Qj-ufA8xZeN75zdV3kLlpmn2YQPeWZdvqxIpJ7vjRxgqb3yYTIbozJheV19Nyi-rfYQEPv8iDHOeIzxGD4cCgCd39zm6-vD-28Wn-vLLx88X7y5rKxTNtWG8MwMAWCa7rhdKULUGZQfMpbXrbiCCGNEKxVvcGTlQYunaKgJEccEMZufo7SHvfl5P0NuiIppR76ObTLzVwTj9d8S7rd6EG80VIZK1JcHzQ4KQstOptAl2a4P3YLOmtFUdaWVBvbgrE8P1DCnrySUL42g8hDlpIotyLgin_wGVEkvRKlagz_4Uf1T9e0cFQA8AG0NKEYYjhGC9GEHv9GIEvRhBY6KLEQpJ_UMqTZnswjIAN95PfXOgQlnZjYO4DAS8hd7FZR59cPfRfwJc2M9y |
| CitedBy_id | crossref_primary_10_1002_bit_28269 crossref_primary_10_1089_jamp_2018_1502 crossref_primary_10_1002_wnan_1665 crossref_primary_10_3390_pharmaceutics14010107 crossref_primary_10_1002_adhm_201801320 crossref_primary_10_1080_17425247_2016_1218463 crossref_primary_10_1016_j_addr_2021_114022 crossref_primary_10_1093_bib_bbab403 crossref_primary_10_1021_jacs_8b12205 crossref_primary_10_2174_1567201817666200214105357 crossref_primary_10_3390_vaccines9070702 crossref_primary_10_1039_C6SC03631G crossref_primary_10_1111_nyas_13347 crossref_primary_10_3390_molecules23112849 crossref_primary_10_1021_acs_nanolett_0c00596 crossref_primary_10_1007_s13721_023_00416_3 crossref_primary_10_1208_s12248_019_0360_8 crossref_primary_10_1016_j_addr_2021_05_030 crossref_primary_10_1016_j_addr_2022_114134 crossref_primary_10_1007_s11914_020_00587_2 crossref_primary_10_1021_acsbiomaterials_9b01135 crossref_primary_10_3390_nano7100332 crossref_primary_10_3390_molecules22050857 crossref_primary_10_3390_molecules22091445 crossref_primary_10_3390_toxics11080674 crossref_primary_10_2217_fvl_2021_0105 crossref_primary_10_1186_s43141_022_00340_5 crossref_primary_10_1002_advs_202407816 crossref_primary_10_1186_s40824_023_00440_4 crossref_primary_10_1039_D4NR01719F crossref_primary_10_1002_smsc_202400324 crossref_primary_10_1016_j_fct_2017_08_023 crossref_primary_10_3389_fimmu_2020_00222 crossref_primary_10_1016_j_jconrel_2022_04_050 crossref_primary_10_3389_fimmu_2019_00133 crossref_primary_10_1093_nargab_lqad037 crossref_primary_10_3390_nano10040787 crossref_primary_10_3390_pharmaceutics17030337 crossref_primary_10_1038_s42003_023_04689_2 crossref_primary_10_1093_milmed_usab177 crossref_primary_10_3389_fimmu_2017_00544 crossref_primary_10_3390_vaccines10030405 crossref_primary_10_1016_j_inoche_2023_110858 crossref_primary_10_1186_s43094_024_00664_8 crossref_primary_10_1128_spectrum_01151_22 crossref_primary_10_1016_j_addr_2018_01_005 crossref_primary_10_2147_IJN_S359118 crossref_primary_10_1016_j_colsurfb_2018_02_061 crossref_primary_10_1016_j_impact_2018_02_008 crossref_primary_10_1590_0037_8682_0661_2022 crossref_primary_10_1039_D3BM00271C crossref_primary_10_3390_pharmaceutics13040473 crossref_primary_10_1016_j_foodcont_2020_107427 crossref_primary_10_1016_j_vaccine_2021_01_003 crossref_primary_10_1080_07391102_2023_2173297 crossref_primary_10_3390_ma14030616 crossref_primary_10_1016_j_mimet_2023_106757 crossref_primary_10_1016_j_cej_2021_134145 crossref_primary_10_1134_S1070428022080115 crossref_primary_10_30895_1991_2919_2023_508 crossref_primary_10_55230_mabjournal_v51i5_2404 crossref_primary_10_1016_j_bioactmat_2023_03_020 crossref_primary_10_1016_j_jim_2021_113125 crossref_primary_10_1016_j_synbio_2024_03_010 crossref_primary_10_1039_D4TB00565A crossref_primary_10_1016_j_ygeno_2020_09_019 crossref_primary_10_1080_1061186X_2019_1588280 crossref_primary_10_1155_2019_4751827 crossref_primary_10_2217_nnm_2016_0199 crossref_primary_10_1134_S1995078018040055 crossref_primary_10_1186_s40364_024_00625_6 crossref_primary_10_1007_s12274_024_6925_6 crossref_primary_10_3389_fimmu_2016_00270 crossref_primary_10_3390_ph15050575 crossref_primary_10_1128_aac_02399_21 crossref_primary_10_1016_j_molmet_2023_101730 crossref_primary_10_1016_j_medidd_2022_100139 crossref_primary_10_1016_j_biotechadv_2023_108200 crossref_primary_10_1080_1547691X_2019_1605553 crossref_primary_10_1016_j_nantod_2023_102032 crossref_primary_10_1038_s41598_020_67749_1 crossref_primary_10_1002_mabi_202100075 crossref_primary_10_1016_j_mtchem_2025_102549 crossref_primary_10_1039_D2NR06718H crossref_primary_10_3390_ijms20194903 crossref_primary_10_1007_s10989_022_10467_1 crossref_primary_10_3390_molecules26237308 crossref_primary_10_7868_S0132342317060100 crossref_primary_10_1039_D1RA06532G crossref_primary_10_1016_j_actbio_2023_03_004 crossref_primary_10_1039_D2CS00968D crossref_primary_10_1021_acsami_3c13948 crossref_primary_10_1002_btm2_10441 crossref_primary_10_1016_j_imbio_2022_152317 crossref_primary_10_1016_j_jmgm_2024_108702 crossref_primary_10_1134_S1068162017060139 crossref_primary_10_3390_pharmaceutics16121521 crossref_primary_10_1080_17425255_2018_1540588 crossref_primary_10_1016_j_jconrel_2022_03_043 crossref_primary_10_3390_molecules26071842 crossref_primary_10_1016_j_xphs_2023_11_001 crossref_primary_10_1039_D1NR06580G crossref_primary_10_1007_s10989_021_10287_9 crossref_primary_10_1111_cpr_13643 crossref_primary_10_3390_molecules27196473 crossref_primary_10_1016_j_addr_2022_114447 crossref_primary_10_1016_j_ijpharm_2024_124686 crossref_primary_10_1080_14760584_2020_1758070 crossref_primary_10_1021_acsabm_4c00537 crossref_primary_10_1016_j_addr_2021_114083 crossref_primary_10_1016_j_phrs_2023_106699 crossref_primary_10_1371_journal_pone_0292156 crossref_primary_10_1002_smll_202204986 crossref_primary_10_1016_j_impact_2017_06_003 crossref_primary_10_1016_j_jddst_2024_105432 crossref_primary_10_3390_pharmaceutics14081614 crossref_primary_10_1007_s13346_021_00924_7 crossref_primary_10_1177_17411343231194755 crossref_primary_10_3389_fimmu_2023_1238046 crossref_primary_10_2217_nnm_2019_0061 crossref_primary_10_1002_adhm_201801177 crossref_primary_10_1016_j_ijbiomac_2024_133188 crossref_primary_10_1016_j_ymeth_2020_03_006 crossref_primary_10_1007_s40097_022_00504_2 crossref_primary_10_3390_nu16050636 crossref_primary_10_1002_slct_202203684 crossref_primary_10_1080_07391102_2023_2278081 crossref_primary_10_1016_j_vetimm_2024_110870 crossref_primary_10_1016_j_ijpharm_2017_07_012 crossref_primary_10_4103_RPS_RPS_91_23 crossref_primary_10_1039_D3TB00632H crossref_primary_10_7717_peerj_9855 |
| Cites_doi | 10.1002/jps.22744 10.1002/jps.22683 10.1002/jps.20237 10.1016/j.jconrel.2007.02.010 10.1002/(SICI)1097-4636(199601)30:1<53::AID-JBM8>3.0.CO;2-Q 10.1016/S0021-9258(17)40291-2 10.1002/jps.23018 10.1007/s11095-012-0934-y 10.1016/j.addr.2009.03.009 10.1055/s-0037-1613600 10.1159/000233512 10.1055/s-0038-1656133 10.1016/0009-3084(86)90075-7 10.1002/jps.21419 10.1038/nbt1332 10.4049/jimmunol.130.3.1390 10.1016/j.molimm.2013.07.014 10.1016/j.jconrel.2003.12.011 10.1002/wnan.88 10.1039/C1AN15745K 10.1021/nl0607636 10.1211/jpp.60.12.0011 10.1056/NEJMoa1203166 10.1016/j.drudis.2014.08.015 10.1016/S0021-9258(17)40292-4 10.1080/15476910600908852 10.1158/1078-0432.CCR-10-0978 10.1016/j.it.2007.07.011 10.1002/jps.21768 10.1208/s12248-014-9587-6 10.1126/science.8248784 10.1016/j.jconrel.2006.08.017 10.1021/mp800032f 10.1023/B:PHAM.0000029275.41323.a6 10.1016/j.ijpharm.2008.06.004 10.1002/jps.21266 10.1081/PDT-100002248 10.1016/j.jconrel.2014.04.003 10.1021/bc200551b 10.1002/jps.22682 10.4049/jimmunol.128.4.1603 10.1124/jpet.104.078113 10.1002/jps.21719 10.1055/s-2002-32667 10.1211/jpp.58.11.0010 10.1002/jps.21778 10.4049/jimmunol.122.3.900 10.4155/bio.14.114 10.1023/A:1011429404950 10.1007/s11095-013-1067-7 10.1073/pnas.95.18.10809 10.3181/00379727-192-42995 10.1002/jps.23225 10.1016/j.tips.2009.11.001 10.1073/pnas.90.14.6385 10.2144/01302rr03 10.1042/bst0120342 10.1016/S0022-3565(24)35391-1 10.1038/nnano.2007.223 10.1016/j.biologicals.2011.01.006 10.1016/j.jconrel.2005.04.003 10.1056/NEJM200205163462015 10.1074/jbc.M805547200 10.1073/pnas.210396197 10.1023/B:PHAM.0000008034.61317.02 10.1016/j.imbio.2012.08.274 10.1124/jpet.103.053413 10.1021/nl015570r 10.1023/B:BMMD.0000042048.18186.ff 10.1002/jps.23254 10.1016/j.jconrel.2006.08.001 10.1517/17425247.2012.720969 10.1002/jps.21530 10.1021/bc980143z 10.1210/en.2009-1082 10.1021/bm100754e 10.1016/j.biomaterials.2007.10.015 10.4049/jimmunol.173.5.3148 10.1016/S0149-2918(02)80075-3 10.1021/ja107583h 10.1002/jps.24184 10.3390/pharmaceutics3010001 10.1161/01.RES.66.3.875 10.1016/j.jconrel.2007.05.015 10.1016/j.taap.2014.03.002 10.1016/j.biologicals.2010.07.002 10.1016/j.ymthe.2005.09.014 10.1016/j.jconrel.2007.11.009 10.1016/j.ijpharm.2010.03.022 10.1007/s11095-011-0621-4 10.1002/jps.21102 10.1038/nri3488 10.1002/cncr.22739 10.1016/S0022-2143(96)90164-X 10.1016/j.jconrel.2013.07.026 10.1248/bpb.b14-00653 10.1016/j.ijpharm.2007.11.005 10.1016/j.jconrel.2009.10.017 10.1016/j.ijpharm.2005.10.010 10.1016/j.jconrel.2006.01.005 10.1007/s11239-006-9011-x |
| ContentType | Journal Article |
| Copyright | 2016 Elsevier Inc. Copyright © 2016 Elsevier Inc. All rights reserved. |
| Copyright_xml | – notice: 2016 Elsevier Inc. – notice: Copyright © 2016 Elsevier Inc. All rights reserved. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 7ST 7U7 C1K SOI OTOTI 5PM |
| DOI | 10.1016/j.taap.2016.01.005 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Environment Abstracts Toxicology Abstracts Environmental Sciences and Pollution Management Environment Abstracts OSTI.GOV PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic Toxicology Abstracts Environment Abstracts Environmental Sciences and Pollution Management |
| DatabaseTitleList | Toxicology Abstracts MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Public Health Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1096-0333 |
| EndPage | 77 |
| ExternalDocumentID | PMC4811736 22689167 26773813 10_1016_j_taap_2016_01_005 S0041008X16300059 |
| Genre | Journal Article Review Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: CCR NIH HHS grantid: HHSN261200800001C – fundername: NCI NIH HHS grantid: HHSN261200800001E |
| GroupedDBID | --- --K --M .~1 0R~ 123 1B1 1RT 1~. 1~5 4.4 457 4G. 5RE 5VS 7-5 71M 8P~ 9JM AABNK AACTN AAEDT AAEDW AAIAV AAIKC AAIKJ AAKOC AALRI AAMNW AAOAW AAQFI AATCM AAXUO ABFRF ABFYP ABJNI ABLST ABMAC ABYKQ ABZDS ACDAQ ACGFO ACGFS ACRLP ADBBV ADEZE AEBSH AEFWE AEKER AENEX AFKWA AFTJW AFXIZ AGHFR AGUBO AGYEJ AHEUO AIEXJ AIKHN AITUG AJBFU AJOXV AKIFW ALCLG ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ AXJTR BKOJK BLECG BLXMC C45 CS3 DM4 EBS EFBJH EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FIRID FNPLU FYGXN G-Q GBLVA IHE J1W KCYFY KOM LG5 M33 M41 MO0 N9A O-L O9- OAUVE OGGZJ OVD OZT P-8 P-9 P2P PC. Q38 RIG ROL RPZ SDF SDG SDP SES SPCBC SSJ SSP SSZ T5K TEORI TWZ WH7 ZU3 ~G- .55 .GJ .HR 29Q 3O- 53G AAQXK AATTM AAXKI AAYWO AAYXX ABEFU ABFNM ABWVN ABXDB ACRPL ACVFH ADCNI ADFGL ADMUD ADNMO AEIPS AEUPX AFFNX AFJKZ AFPUW AGCQF AGQPQ AGRNS AHHHB AIGII AIIUN AKBMS AKRWK AKYEP ANKPU APXCP ASPBG AVWKF AZFZN BNPGV CAG CITATION COF FEDTE FGOYB G-2 HMT HVGLF HZ~ R2- SEW SPT SSH UHS WUQ X7M XJT XPP Y6R ZGI ZKB ZMT ZXP ~KM CGR CUY CVF ECM EFKBS EIF NPM 7X8 7ST 7U7 C1K SOI AALMO AAPBV ABPIF ABPTK ABQIS EFJIC OTOTI 5PM |
| ID | FETCH-LOGICAL-c582t-a349afeeec3799d58528be8cf047ccb9f151a56584609a7f21c2bc81e18453a03 |
| IEDL.DBID | .~1 |
| ISSN | 0041-008X 1096-0333 |
| IngestDate | Thu Aug 21 13:46:48 EDT 2025 Fri May 19 01:41:06 EDT 2023 Thu Jul 10 18:46:12 EDT 2025 Thu Jul 10 22:21:26 EDT 2025 Mon Jul 21 05:50:51 EDT 2025 Thu Jul 03 08:39:40 EDT 2025 Thu Apr 24 22:57:11 EDT 2025 Fri Feb 23 02:29:42 EST 2024 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | Nanoparticles Anaphylaxis Immunogenicity Cytokines Antigenicity Antibody Preclinical Phagocytosis |
| Language | English |
| License | Copyright © 2016 Elsevier Inc. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c582t-a349afeeec3799d58528be8cf047ccb9f151a56584609a7f21c2bc81e18453a03 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/4811736 |
| PMID | 26773813 |
| PQID | 1777075683 |
| PQPubID | 23479 |
| PageCount | 8 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_4811736 osti_scitechconnect_22689167 proquest_miscellaneous_1785245142 proquest_miscellaneous_1777075683 pubmed_primary_26773813 crossref_primary_10_1016_j_taap_2016_01_005 crossref_citationtrail_10_1016_j_taap_2016_01_005 elsevier_sciencedirect_doi_10_1016_j_taap_2016_01_005 |
| PublicationCentury | 2000 |
| PublicationDate | 2016-05-15 |
| PublicationDateYYYYMMDD | 2016-05-15 |
| PublicationDate_xml | – month: 05 year: 2016 text: 2016-05-15 day: 15 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Toxicology and applied pharmacology |
| PublicationTitleAlternate | Toxicol Appl Pharmacol |
| PublicationYear | 2016 |
| Publisher | Elsevier Inc |
| Publisher_xml | – name: Elsevier Inc |
| References | Liu, Swift, Torraca, Nashed-Samuel, Wen, Jiang, Vance, Mire-Sluis, Freund, Davis, Narhi (bb0365) 2010; 64 Schellekens, Hennink, Brinks (bb0480) 2013; 30 Alving (bb0035) 1986; 40 Andreev, Babakhin, Petrukhina, Romanova, Parnes, Petrov (bb0045) 2000; 370 Hermeling, Schellekens, Crommelin, Jiskoot (bb0230) 2003; 20 Richards, Aronson, Schoenbechler, Diggs, Alving (bb0440) 1983; 130 Gershon, Luksenburg, Cote, Braun (bb0205) 2002; 346 Ennis, Pritchard, Nakamura, Coulon, Yang, Visor, Lee (bb0180) 2001; 6 Rosenberg (bb0455) 2003; 112 Liu, Randolph, Carpenter (bb0370) 2012; 101 Bachmann, Rohrer, Kundig, Burki, Hengartner, Zinkernagel (bb0070) 1993; 262 Hendrickson, Fedyunina, Zherdev, Solopova, Sveshnikov, Dzantiev (bb0225) 2012; 137 Schellekens (bb0475) 2002; 24 Abuchowski, McCoy, Palczuk, van Es, Davis (bb0010) 1977; 252 Chen, Wilson, Das, Coughlin, Erlanger (bb0125) 1998; 95 Jiang, Nashed-Samuel, Li, Liu, Pollastrini, Mallard, Wen, Fujimori, Pallitto, Donahue, Chu, Torraca, Vance, Mire-Sluis, Freund, Davis, Narhi (bb0290) 2009; 98 Nguyen, O'Rear, Johnson, Patterson, Whitsett, Bhakta (bb0405) 1990; 66 Dams, Laverman, Oyen, Storm, Scherphof, van Der Meer, Corstens, Boerman (bb0145) 2000; 292 Dobrovolskaia (bb0155) 2013 Watanabe, Nakanishi, Umetsu, Kumagai (bb0570) 2008; 283 Ishida, Harada, Wang, Ichihara, Irimura, Kiwada (bb0255) 2005; 105 Nguyen, O'Rear, Johnson, Lu, Fung (bb0400) 1989; 192 Reddy, van der Vlies, Simeoni, Angeli, Randolph, O'Neil, Lee, Swartz, Hubbell (bb0435) 2007; 25 Dobrovolskaia, Aggarwal, Hall, McNeil (bb0165) 2008; 5 Aggarwal, Hall, McLeland, Dobrovolskaia, McNeil (bb0025) 2009; 61 Monopoli, Walczyk, Campbell, Elia, Lynch, Bombelli, Dawson (bb0390) 2011; 133 Smith, Simon, Baker (bb0510) 2013; 13 Van Beers, Gilli, Schellekens, Randolph, Jiskoot (bb0555) 2012; 101 Ishihara, Maeda, Sakamoto, Takasaki, Shigyo, Ishida, Kiwada, Mizushima, Mizushima (bb0285) 2010; 11 Alving, Swartz, Wassef, Ribas, Herderick, Virmani, Kolodgie, Matyas, Cornhill (bb0040) 1996; 127 Ishida, Atobe, Wang, Kiwada (bb0260) 2006; 115 Ichihara, Shimizu, Imoto, Hashiguchi, Uehara, Ishida, Kiwada (bb0240) 2011; 3 Jiskoot, Randolph, Volkin, Middaugh, Schoneich, Winter, Friess, Crommelin, Carpenter (bb0295) 2012; 101 Tatarewicz, Mytych, Manning, Swanson, Moxness, Chirmule (bb0535) 2014; 6 Masalova, Shepelev, Atanadze, Parnes, Romanova, Vol'pina, Semiletov Iu, Kushch (bb0380) 1999; 369 Tagami, Nakamura, Shimizu, Yamazaki, Ishida, Kiwada (bb0530) 2010; 142 Charrois, Allen (bb0120) 2003; 306 Saifer, Williams, Sobczyk, Michaels, Sherman (bb0465) 2014; 57 Arima, Toda, Iwata (bb0055) 2008; 29 Dykman, Sumaroka, Staroverov, Zaitseva, Bogatyrev (bb0170) 2004 Schuster, Neidig, Alving, Alving (bb0485) 1979; 122 Hashimoto, Shimizu, Mima, Abu Lila, Ishida, Kiwada (bb0215) 2014; 277 Roberts, Bhalgat, Zera (bb0450) 1996; 30 Abuchowski, van Es, Palczuk, Davis (bb0015) 1977; 252 Ishida, Ichihara, Wang, Yamamoto, Kimura, Majima, Kiwada (bb0270) 2006; 112 Kunamneni, Abdelghani, Ellaiah (bb0330) 2007; 23 Xiang, Selomulya, Ho, Apostolopoulos, Plebanski (bb0575) 2010; 2 Ishida, Kashima, Kiwada (bb0280) 2008; 126 Sauerborn, Brinks, Jiskoot, Schellekens (bb0470) 2010; 31 Banerji, Kenny, Scher, Alving (bb0075) 1982; 128 Lee, Parthasarathy, Botwin, Kunneman, Rowold, Lange, Klover, Abegg, Zobel, Beck, Miller, Hood, Monahan, McKearn, Jansson, Voliva (bb0345) 2004; 6 Lee, Parthasarathy, Duffin, Botwin, Zobel, Beck, Lange, Kunneman, Janssen, Rowold, Voliva (bb0340) 2001; 3 Judge, McClintock, Phelps, Maclachlan (bb0300) 2006; 13 Perkins, Vaughan, Plavin, Daley, Rauch, Lee, Janoff (bb0420) 1997; 77 Tyagi, Randolph, Dong, Maloney, Hitscherich, Carpenter (bb0550) 2009; 98 Alving (bb0030) 1984; 12 Semple, Harasym, Clow, Ansell, Klimuk, Hope (bb0495) 2005; 312 Ishida, Ichihara, Wang, Kiwada (bb0265) 2006; 115 Armstrong, Hempel, Koling, Chan, Fisher, Meiselman, Garratty (bb0060) 2007; 110 Fifis, Gamvrellis, Crimeen-Irwin, Pietersz, Li, Mottram, McKenzie, Plebanski (bb0190) 2004; 173 Fradkin, Carpenter, Randolph (bb0195) 2011; 100 Ishida, Ichikawa, Ichihara, Sadzuka, Kiwada (bb0250) 2004; 95 Parenky, Myler, Amaravadi, Bechtold-Peters, Rosenberg, Kirshner, Quarmby (bb0415) 2014; 16 Li, Cao, Wang, Zhao, Deng, Wei, Yang, Cui (bb0355) 2012; 101 Agashe, Dutta, Garg, Jain (bb0020) 2006; 58 Verhoef, Carpenter, Anchordoquy, Schellekens (bb0560) 2014; 19 Wang, Ishida, Kiwada (bb0565) 2007; 119 Cui, Li, Wang, Li, Zhang, Yang (bb0140) 2008; 60 Zolnik, Gonzalez-Fernandez, Sadrieh, Dobrovolskaia (bb0580) 2010; 151 Ishida, Kiwada (bb0245) 2008; 354 Shimizu, Ishida, Kiwada (bb0505) 2013; 218 Richter, Akerblom (bb0445) 1984; 74 Carpenter, Cherney, Lubinecki, Ma, Marszal, Mire-Sluis, Nikolai, Novak, Ragheb, Simak (bb0105) 2010; 38 Sherman, Williams, Sobczyk, Michaels, Saifer (bb0500) 2012; 23 Barbas, Rosenblum, Lerner (bb0080) 1993; 90 Koide, Asai, Hatanaka, Urakami, Ishii, Kenjo, Nishihara, Yokoyama, Ishida, Kiwada, Oku (bb0315) 2008; 362 Leach, O'Rear, Patterson, Miao, Johnson (bb0335) 2003; 90 Murphy (bb0395) 2012 Eggebeen (bb0175) 2007; 76 Cheng, Wu, Wu, Chern, Roffler (bb0130) 1999; 10 Koide, Asai, Hatanaka, Akai, Ishii, Kenjo, Ishida, Kiwada, Tsukada, Oku (bb0320) 2010; 392 Hashimoto, Shimizu, Abu Lila, Ishida, Kiwada (bb0220) 2015; 38 Erlanger, Chen, Zhu, Brus (bb0185) 2001; 1 Libutti, Paciotti, Byrnes, Alexander, Gannon, Walker, Seidel, Yuldasheva, Tamarkin (bb0360) 2010; 16 Owens, Peppas (bb0410) 2006; 307 Braden, Goldbaum, Chen, Kirschner, Wilson, Erlanger (bb0090) 2000; 97 Macdougall, Provenzano, Sharma, Spinowitz, Schmidt, Pergola, Zabaneh, Tong-Starksen, Mayo, Tang, Polu, Duliege, Fishbane (bb0375) 2013; 368 Ramani, Miclea, Purohit, Mager, Straubinger, Balu-Iyer (bb0425) 2008; 97 Saadati, Dadashzadeh, Abbasian, Soleimanjahi (bb0460) 2013; 30 Abu Lila, Kiwada, Ishida (bb0005) 2013; 172 Buttel, Chamberlain, Chowers, Ehmann, Greinacher, Jefferis, Kramer, Kropshofer, Lloyd, Lubiniecki, Krause, Mire-Sluis, Platts-Mills, Ragheb, Reipert, Schellekens, Seitz, Stas, Subramanyam, Thorpe, Trouvin, Weise, Windisch, Schneider (bb0095) 2011; 39 Mire-Sluis, Cherney, Madsen, Polozova, Rosenberg, Smith, Arora, Narhi (bb0385) 2011; 9 Krayukhina, Tsumoto, Uchiyama, Fukui (bb0325) 2015; 104 Hashimoto, Abu Lila, Shimizu, Ishida, Kiwada (bb0210) 2014; 184 Artzy Schnirman, Zahavi, Yeger, Rosenfeld, Benhar, Reiter, Sivan (bb0065) 2006; 6 Klinge, Ananyeva, Hauser, Saenko (bb0310) 2002; 28 Seidl, Hainzl, Richter, Fischer, Bohm, Deutel, Hartinger, Windisch, Casadevall, London, Macdougall (bb0490) 2012; 29 Tsai, Cheng, Roffler (bb0545) 2001; 30 Ishida, Wang, Shimizu, Nawata, Kiwada (bb0275) 2007; 122 Carpenter, Randolph, Jiskoot, Crommelin, Middaugh, Winter, Fan, Kirshner, Verthelyi, Kozlowski, Clouse, Swann, Rosenberg, Cherney (bb0100) 2009; 98 Ramani, Purohit, Miclea, Gaitonde, Straubinger, Balu-Iyer (bb0430) 2008; 97 Garay, El-Gewely, Armstrong, Garratty, Richette (bb0200) 2012; 9 Chi, Weickmann, Carpenter, Manning, Randolph (bb0135) 2005; 94 Andreev, Babakhin, Petrukhina, Romanova, Parnes, Petrov (bb0050) 2000; 370 Hermeling, Crommelin, Schellekens, Jiskoot (bb0235) 2004; 21 Kaminskas, McLeod, Porter, Boyd (bb0305) 2011; 100 De Groot, Scott (bb0150) 2007; 28 Dobrovolskaia, McNeil (bb0160) 2007; 2 Leger, Arndt, Garratty, Armstrong, Meiselman, Fisher (bb0350) 2001; 41 Bee, Chiu, Sawicki, Stevenson, Chatterjee, Freund, Carpenter, Randolph (bb0085) 2009; 98 Swanson (bb0525) 2006; 3 Chamberlain, Mire-Sluis (bb0110) 2003; 112 Thirumangalathu, Krishnan, Ricci, Brems, Randolph, Carpenter (bb0540) 2009; 98 Liu (10.1016/j.taap.2016.01.005_bb0365) 2010; 64 Ramani (10.1016/j.taap.2016.01.005_bb0430) 2008; 97 Ishida (10.1016/j.taap.2016.01.005_bb0260) 2006; 115 Tsai (10.1016/j.taap.2016.01.005_bb0545) 2001; 30 Wang (10.1016/j.taap.2016.01.005_bb0565) 2007; 119 Zolnik (10.1016/j.taap.2016.01.005_bb0580) 2010; 151 Artzy Schnirman (10.1016/j.taap.2016.01.005_bb0065) 2006; 6 Nguyen (10.1016/j.taap.2016.01.005_bb0400) 1989; 192 Abu Lila (10.1016/j.taap.2016.01.005_bb0005) 2013; 172 Murphy (10.1016/j.taap.2016.01.005_bb0395) 2012 Semple (10.1016/j.taap.2016.01.005_bb0495) 2005; 312 Nguyen (10.1016/j.taap.2016.01.005_bb0405) 1990; 66 Armstrong (10.1016/j.taap.2016.01.005_bb0060) 2007; 110 Ishida (10.1016/j.taap.2016.01.005_bb0280) 2008; 126 Reddy (10.1016/j.taap.2016.01.005_bb0435) 2007; 25 Ishida (10.1016/j.taap.2016.01.005_bb0270) 2006; 112 Perkins (10.1016/j.taap.2016.01.005_bb0420) 1997; 77 Jiskoot (10.1016/j.taap.2016.01.005_bb0295) 2012; 101 Saifer (10.1016/j.taap.2016.01.005_bb0465) 2014; 57 Tatarewicz (10.1016/j.taap.2016.01.005_bb0535) 2014; 6 Owens (10.1016/j.taap.2016.01.005_bb0410) 2006; 307 Macdougall (10.1016/j.taap.2016.01.005_bb0375) 2013; 368 Hermeling (10.1016/j.taap.2016.01.005_bb0230) 2003; 20 Abuchowski (10.1016/j.taap.2016.01.005_bb0010) 1977; 252 Alving (10.1016/j.taap.2016.01.005_bb0040) 1996; 127 Fifis (10.1016/j.taap.2016.01.005_bb0190) 2004; 173 Tagami (10.1016/j.taap.2016.01.005_bb0530) 2010; 142 Ishihara (10.1016/j.taap.2016.01.005_bb0285) 2010; 11 Ishida (10.1016/j.taap.2016.01.005_bb0250) 2004; 95 Alving (10.1016/j.taap.2016.01.005_bb0035) 1986; 40 Dams (10.1016/j.taap.2016.01.005_bb0145) 2000; 292 Sherman (10.1016/j.taap.2016.01.005_bb0500) 2012; 23 Leach (10.1016/j.taap.2016.01.005_bb0335) 2003; 90 Hashimoto (10.1016/j.taap.2016.01.005_bb0215) 2014; 277 Carpenter (10.1016/j.taap.2016.01.005_bb0105) 2010; 38 Koide (10.1016/j.taap.2016.01.005_bb0320) 2010; 392 Abuchowski (10.1016/j.taap.2016.01.005_bb0015) 1977; 252 Xiang (10.1016/j.taap.2016.01.005_bb0575) 2010; 2 Judge (10.1016/j.taap.2016.01.005_bb0300) 2006; 13 Hashimoto (10.1016/j.taap.2016.01.005_bb0210) 2014; 184 Klinge (10.1016/j.taap.2016.01.005_bb0310) 2002; 28 Li (10.1016/j.taap.2016.01.005_bb0355) 2012; 101 De Groot (10.1016/j.taap.2016.01.005_bb0150) 2007; 28 Hendrickson (10.1016/j.taap.2016.01.005_bb0225) 2012; 137 Saadati (10.1016/j.taap.2016.01.005_bb0460) 2013; 30 Schuster (10.1016/j.taap.2016.01.005_bb0485) 1979; 122 Sauerborn (10.1016/j.taap.2016.01.005_bb0470) 2010; 31 Garay (10.1016/j.taap.2016.01.005_bb0200) 2012; 9 Dobrovolskaia (10.1016/j.taap.2016.01.005_bb0155) 2013 Lee (10.1016/j.taap.2016.01.005_bb0340) 2001; 3 Hermeling (10.1016/j.taap.2016.01.005_bb0235) 2004; 21 Ishida (10.1016/j.taap.2016.01.005_bb0255) 2005; 105 Seidl (10.1016/j.taap.2016.01.005_bb0490) 2012; 29 Barbas (10.1016/j.taap.2016.01.005_bb0080) 1993; 90 Ishida (10.1016/j.taap.2016.01.005_bb0245) 2008; 354 Mire-Sluis (10.1016/j.taap.2016.01.005_bb0385) 2011; 9 Chen (10.1016/j.taap.2016.01.005_bb0125) 1998; 95 Fradkin (10.1016/j.taap.2016.01.005_bb0195) 2011; 100 Ichihara (10.1016/j.taap.2016.01.005_bb0240) 2011; 3 Liu (10.1016/j.taap.2016.01.005_bb0370) 2012; 101 Masalova (10.1016/j.taap.2016.01.005_bb0380) 1999; 369 Buttel (10.1016/j.taap.2016.01.005_bb0095) 2011; 39 Erlanger (10.1016/j.taap.2016.01.005_bb0185) 2001; 1 Libutti (10.1016/j.taap.2016.01.005_bb0360) 2010; 16 Aggarwal (10.1016/j.taap.2016.01.005_bb0025) 2009; 61 Cheng (10.1016/j.taap.2016.01.005_bb0130) 1999; 10 Lee (10.1016/j.taap.2016.01.005_bb0345) 2004; 6 Kunamneni (10.1016/j.taap.2016.01.005_bb0330) 2007; 23 Parenky (10.1016/j.taap.2016.01.005_bb0415) 2014; 16 Jiang (10.1016/j.taap.2016.01.005_bb0290) 2009; 98 Swanson (10.1016/j.taap.2016.01.005_bb0525) 2006; 3 Ramani (10.1016/j.taap.2016.01.005_bb0425) 2008; 97 Bee (10.1016/j.taap.2016.01.005_bb0085) 2009; 98 Ishida (10.1016/j.taap.2016.01.005_bb0275) 2007; 122 Kaminskas (10.1016/j.taap.2016.01.005_bb0305) 2011; 100 Rosenberg (10.1016/j.taap.2016.01.005_bb0455) 2003; 112 Dobrovolskaia (10.1016/j.taap.2016.01.005_bb0165) 2008; 5 Schellekens (10.1016/j.taap.2016.01.005_bb0480) 2013; 30 Verhoef (10.1016/j.taap.2016.01.005_bb0560) 2014; 19 Andreev (10.1016/j.taap.2016.01.005_bb0050) 2000; 370 Chi (10.1016/j.taap.2016.01.005_bb0135) 2005; 94 Roberts (10.1016/j.taap.2016.01.005_bb0450) 1996; 30 Ennis (10.1016/j.taap.2016.01.005_bb0180) 2001; 6 Braden (10.1016/j.taap.2016.01.005_bb0090) 2000; 97 Koide (10.1016/j.taap.2016.01.005_bb0315) 2008; 362 Watanabe (10.1016/j.taap.2016.01.005_bb0570) 2008; 283 Cui (10.1016/j.taap.2016.01.005_bb0140) 2008; 60 Chamberlain (10.1016/j.taap.2016.01.005_bb0110) 2003; 112 Richter (10.1016/j.taap.2016.01.005_bb0445) 1984; 74 Gershon (10.1016/j.taap.2016.01.005_bb0205) 2002; 346 Agashe (10.1016/j.taap.2016.01.005_bb0020) 2006; 58 Bachmann (10.1016/j.taap.2016.01.005_bb0070) 1993; 262 Hashimoto (10.1016/j.taap.2016.01.005_bb0220) 2015; 38 Richards (10.1016/j.taap.2016.01.005_bb0440) 1983; 130 Smith (10.1016/j.taap.2016.01.005_bb0510) 2013; 13 Monopoli (10.1016/j.taap.2016.01.005_bb0390) 2011; 133 Carpenter (10.1016/j.taap.2016.01.005_bb0100) 2009; 98 Ishida (10.1016/j.taap.2016.01.005_bb0265) 2006; 115 Shimizu (10.1016/j.taap.2016.01.005_bb0505) 2013; 218 Arima (10.1016/j.taap.2016.01.005_bb0055) 2008; 29 Thirumangalathu (10.1016/j.taap.2016.01.005_bb0540) 2009; 98 Andreev (10.1016/j.taap.2016.01.005_bb0045) 2000; 370 Dobrovolskaia (10.1016/j.taap.2016.01.005_bb0160) 2007; 2 Leger (10.1016/j.taap.2016.01.005_bb0350) 2001; 41 Eggebeen (10.1016/j.taap.2016.01.005_bb0175) 2007; 76 Krayukhina (10.1016/j.taap.2016.01.005_bb0325) 2015; 104 Banerji (10.1016/j.taap.2016.01.005_bb0075) 1982; 128 Tyagi (10.1016/j.taap.2016.01.005_bb0550) 2009; 98 Charrois (10.1016/j.taap.2016.01.005_bb0120) 2003; 306 Alving (10.1016/j.taap.2016.01.005_bb0030) 1984; 12 Dykman (10.1016/j.taap.2016.01.005_bb0170) 2004 Schellekens (10.1016/j.taap.2016.01.005_bb0475) 2002; 24 Van Beers (10.1016/j.taap.2016.01.005_bb0555) 2012; 101 |
| References_xml | – volume: 112 start-page: 15 year: 2003 end-page: 21 ident: bb0455 article-title: Immunogenicity of biological therapeutics: a hierarchy of concerns publication-title: Dev. Biol. (Basel) – volume: 252 start-page: 3582 year: 1977 end-page: 3586 ident: bb0010 article-title: Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase publication-title: J. Biol. Chem. – volume: 39 start-page: 100 year: 2011 end-page: 109 ident: bb0095 article-title: Taking immunogenicity assessment of therapeutic proteins to the next level publication-title: Biologicals – volume: 137 start-page: 98 year: 2012 end-page: 105 ident: bb0225 article-title: Production of monoclonal antibodies against fullerene C60 and development of a fullerene enzyme immunoassay publication-title: Analyst – volume: 126 start-page: 162 year: 2008 end-page: 165 ident: bb0280 article-title: The contribution of phagocytic activity of liver macrophages to the accelerated blood clearance (ABC) phenomenon of PEGylated liposomes in rats publication-title: J. Control. Release – volume: 61 start-page: 428 year: 2009 end-page: 437 ident: bb0025 article-title: Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy publication-title: Adv. Drug Deliv. Rev. – volume: 1 start-page: 465 year: 2001 end-page: 467 ident: bb0185 article-title: Binding of an anti-fullerene IgG monoclonal antibody to single wall carbon nanotubes publication-title: Nano Lett. – volume: 11 start-page: 2700 year: 2010 end-page: 2706 ident: bb0285 article-title: Evasion of the accelerated blood clearance phenomenon by coating of nanoparticles with various hydrophilic polymers publication-title: Biomacromolecules – start-page: 86 year: 2004 end-page: 91 ident: bb0170 article-title: Immunogenic properties of the colloidal gold publication-title: Izv. Akad. Nauk Ser. Biol. – volume: 3 start-page: 53 year: 2001 end-page: 59 ident: bb0340 article-title: Recognition properties of antibodies to PAMAM dendrimers and their use in immune detection of dendrimers publication-title: Biomed. Microdevices – volume: 16 start-page: 499 year: 2014 end-page: 503 ident: bb0415 article-title: New FDA draft guidance on immunogenicity publication-title: AAPS J. – volume: 101 start-page: 187 year: 2012 end-page: 199 ident: bb0555 article-title: Immunogenicity of recombinant human interferon beta interacting with particles of glass, metal, and polystyrene publication-title: J. Pharm. Sci. – volume: 74 start-page: 36 year: 1984 end-page: 39 ident: bb0445 article-title: Polyethylene glycol reactive antibodies in man: titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and in healthy blood donors publication-title: Int. Arch. Allergy Appl. Immunol. – volume: 115 start-page: 243 year: 2006 end-page: 250 ident: bb0265 article-title: Spleen plays an important role in the induction of accelerated blood clearance of PEGylated liposomes publication-title: J. Control. Release – volume: 292 start-page: 1071 year: 2000 end-page: 1079 ident: bb0145 article-title: Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes publication-title: J. Pharmacol. Exp. Ther. – volume: 6 start-page: 1870 year: 2006 end-page: 1874 ident: bb0065 article-title: Antibody molecules discriminate between crystalline facets of a gallium arsenide semiconductor publication-title: Nano Lett. – volume: 262 start-page: 1448 year: 1993 end-page: 1451 ident: bb0070 article-title: The influence of antigen organization on B cell responsiveness publication-title: Science – volume: 90 start-page: 6385 year: 1993 end-page: 6389 ident: bb0080 article-title: Direct selection of antibodies that coordinate metals from semisynthetic combinatorial libraries publication-title: Proc. Natl. Acad. Sci. U. S. A. – volume: 362 start-page: 197 year: 2008 end-page: 200 ident: bb0315 article-title: Particle size-dependent triggering of accelerated blood clearance phenomenon publication-title: Int. J. Pharm. – volume: 172 start-page: 38 year: 2013 end-page: 47 ident: bb0005 article-title: The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage publication-title: J. Control. Release – volume: 100 start-page: 4953 year: 2011 end-page: 4964 ident: bb0195 article-title: Glass particles as an adjuvant: a model for adverse immunogenicity of therapeutic proteins publication-title: J. Pharm. Sci. – volume: 13 start-page: 592 year: 2013 end-page: 605 ident: bb0510 article-title: Applications of nanotechnology for immunology publication-title: Nat. Rev. Immunol. – volume: 2 start-page: 469 year: 2007 end-page: 478 ident: bb0160 article-title: Immunological properties of engineered nanomaterials publication-title: Nat. Nanotechnol. – volume: 21 start-page: 897 year: 2004 end-page: 903 ident: bb0235 article-title: Structure–immunogenicity relationships of therapeutic proteins publication-title: Pharm. Res. – volume: 98 start-page: 4695 year: 2009 end-page: 4710 ident: bb0290 article-title: Tungsten-induced protein aggregation: solution behavior publication-title: J. Pharm. Sci. – volume: 6 start-page: 393 year: 2001 end-page: 405 ident: bb0180 article-title: Glass vials for small volume parenterals: influence of drug and manufacturing processes on glass delamination publication-title: Pharm. Dev. Technol. – volume: 130 start-page: 1390 year: 1983 end-page: 1394 ident: bb0440 article-title: Antibodies reactive with liposomal phospholipids are produced during experimental publication-title: J. Immunol. – volume: 41 start-page: 29S year: 2001 ident: bb0350 article-title: Normal donor sera can contain antibodies to polyethylene glycol (PEG) publication-title: Transfusion – volume: 9 start-page: 1319 year: 2012 end-page: 1323 ident: bb0200 article-title: Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents publication-title: Expert. Opin. Drug Deliv. – volume: 346 start-page: 1584 year: 2002 end-page: 1586 ident: bb0205 article-title: Pure red-cell aplasia and recombinant erythropoietin publication-title: N. Engl. J. Med. – volume: 97 start-page: 12193 year: 2000 end-page: 12197 ident: bb0090 article-title: X-ray crystal structure of an anti-Buckminsterfullerene antibody fab fragment: biomolecular recognition of C(60) publication-title: Proc. Natl. Acad. Sci. U. S. A. – volume: 128 start-page: 1603 year: 1982 end-page: 1607 ident: bb0075 article-title: Antibodies against liposomes in normal and immune-defective mice publication-title: J. Immunol. – volume: 142 start-page: 160 year: 2010 end-page: 166 ident: bb0530 article-title: CpG motifs in pDNA-sequences increase anti-PEG IgM production induced by PEG-coated pDNA-lipoplexes publication-title: J. Control. Release – volume: 218 start-page: 725 year: 2013 end-page: 732 ident: bb0505 article-title: Transport of PEGylated liposomes from the splenic marginal zone to the follicle in the induction phase of the accelerated blood clearance phenomenon publication-title: Immunobiology – volume: 38 start-page: 417 year: 2015 end-page: 424 ident: bb0220 article-title: Relationship between the concentration of anti-polyethylene glycol (PEG) immunoglobulin M (IgM) and the intensity of the accelerated blood clearance (ABC) phenomenon against PEGylated liposomes in mice publication-title: Biol. Pharm. Bull. – volume: 30 start-page: 985 year: 2013 end-page: 995 ident: bb0460 article-title: Accelerated blood clearance of PEGylated PLGA nanoparticles following repeated injections: effects of polymer dose, PEG coating, and encapsulated anticancer drug publication-title: Pharm. Res. – volume: 127 start-page: 40 year: 1996 end-page: 49 ident: bb0040 article-title: Immunization with cholesterol-rich liposomes induces anti-cholesterol antibodies and reduces diet-induced hypercholesterolemia and plaque formation publication-title: J. Lab. Clin. Med. – volume: 20 start-page: 1903 year: 2003 end-page: 1907 ident: bb0230 article-title: Micelle-associated protein in epoetin formulations: a risk factor for immunogenicity? publication-title: Pharm. Res. – volume: 312 start-page: 1020 year: 2005 end-page: 1026 ident: bb0495 article-title: Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic acid publication-title: J. Pharmacol. Exp. Ther. – volume: 58 start-page: 1491 year: 2006 end-page: 1498 ident: bb0020 article-title: Investigations on the toxicological profile of functionalized fifth-generation poly (propylene imine) dendrimer publication-title: J. Pharm. Pharmacol. – volume: 119 start-page: 236 year: 2007 end-page: 244 ident: bb0565 article-title: Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes publication-title: J. Control. Release – volume: 306 start-page: 1058 year: 2003 end-page: 1067 ident: bb0120 article-title: Multiple injections of pegylated liposomal Doxorubicin: pharmacokinetics and therapeutic activity publication-title: J. Pharmacol. Exp. Ther. – volume: 392 start-page: 218 year: 2010 end-page: 223 ident: bb0320 article-title: T cell-independent B cell response is responsible for ABC phenomenon induced by repeated injection of PEGylated liposomes publication-title: Int. J. Pharm. – volume: 29 start-page: 551 year: 2008 end-page: 560 ident: bb0055 article-title: Complement activation on surfaces modified with ethylene glycol units publication-title: Biomaterials – volume: 29 start-page: 1454 year: 2012 end-page: 1467 ident: bb0490 article-title: Tungsten-induced denaturation and aggregation of epoetin alfa during primary packaging as a cause of immunogenicity publication-title: Pharm. Res. – volume: 173 start-page: 3148 year: 2004 end-page: 3154 ident: bb0190 article-title: Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors publication-title: J. Immunol. – volume: 95 start-page: 10809 year: 1998 end-page: 10813 ident: bb0125 article-title: Antigenicity of fullerenes: antibodies specific for fullerenes and their characteristics publication-title: Proc. Natl. Acad. Sci. U. S. A. – volume: 77 start-page: 1174 year: 1997 end-page: 1178 ident: bb0420 article-title: Streptokinase entrapment in interdigitation-fusion liposomes improves thrombolysis in an experimental rabbit model publication-title: Thromb. Haemost. – volume: 9 start-page: 38 year: 2011 end-page: 43 ident: bb0385 article-title: Analysis and immunogenic potential of aggregates and particles: a practical approach, part 2 publication-title: BioProcess International – volume: 57 start-page: 236 year: 2014 end-page: 246 ident: bb0465 article-title: Selectivity of binding of PEGs and PEG-like oligomers to anti-PEG antibodies induced by methoxyPEG-proteins publication-title: Mol. Immunol. – volume: 252 start-page: 3578 year: 1977 end-page: 3581 ident: bb0015 article-title: Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol publication-title: J. Biol. Chem. – volume: 101 start-page: 3864 year: 2012 end-page: 3876 ident: bb0355 article-title: Accelerated blood clearance of pegylated liposomal topotecan: influence of polyethylene glycol grafting density and animal species publication-title: J. Pharm. Sci. – volume: 12 start-page: 342 year: 1984 end-page: 344 ident: bb0030 article-title: Natural antibodies against phospholipids and liposomes in humans publication-title: Biochem. Soc. Trans. – volume: 112 start-page: 3 year: 2003 end-page: 11 ident: bb0110 article-title: An overview of scientific and regulatory issues for the immunogenicity of biological products publication-title: Dev. Biol. (Basel) – volume: 10 start-page: 520 year: 1999 end-page: 528 ident: bb0130 article-title: Accelerated clearance of polyethylene glycol-modified proteins by anti-polyethylene glycol IgM publication-title: Bioconjug. Chem. – volume: 112 start-page: 15 year: 2006 end-page: 25 ident: bb0270 article-title: Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes publication-title: J. Control. Release – volume: 13 start-page: 328 year: 2006 end-page: 337 ident: bb0300 article-title: Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes publication-title: Mol. Ther. – volume: 28 start-page: 309 year: 2002 end-page: 322 ident: bb0310 article-title: Hemophilia A—from basic science to clinical practice publication-title: Semin. Thromb. Hemost. – volume: 97 start-page: 1386 year: 2008 end-page: 1398 ident: bb0425 article-title: Phosphatidylserine containing liposomes reduce immunogenicity of recombinant human factor VIII (rFVIII) in a murine model of hemophilia A publication-title: J. Pharm. Sci. – volume: 370 start-page: 4 year: 2000 end-page: 7 ident: bb0050 article-title: Immunogenic and allergenic properties of fulleren conjugates with aminoacids and proteins publication-title: Dokl. Biochem. – volume: 76 start-page: 801 year: 2007 end-page: 808 ident: bb0175 article-title: Gout: an update publication-title: Am. Fam. Physician – volume: 66 start-page: 875 year: 1990 end-page: 878 ident: bb0405 article-title: Accelerated thrombolysis and reperfusion in a canine model of myocardial infarction by liposomal encapsulation of streptokinase publication-title: Circ. Res. – volume: 100 start-page: 5069 year: 2011 end-page: 5077 ident: bb0305 article-title: Differences in colloidal structure of PEGylated nanomaterials dictate the likelihood of accelerated blood clearance publication-title: J. Pharm. Sci. – volume: 370 start-page: 261 year: 2000 end-page: 264 ident: bb0045 article-title: Immunogenic and allergenic properties of fulleren conjugates with aminoacids and proteins publication-title: Dokl. Biochem. – volume: 60 start-page: 1651 year: 2008 end-page: 1657 ident: bb0140 article-title: Repeated injection of pegylated liposomal antitumour drugs induces the disappearance of the rapid distribution phase publication-title: J. Pharm. Pharmacol. – volume: 31 start-page: 53 year: 2010 end-page: 59 ident: bb0470 article-title: Immunological mechanism underlying the immune response to recombinant human protein therapeutics publication-title: Trends Pharmacol. Sci. – volume: 30 start-page: 1729 year: 2013 end-page: 1734 ident: bb0480 article-title: The immunogenicity of polyethylene glycol: facts and fiction publication-title: Pharm. Res. – volume: 2 start-page: 205 year: 2010 end-page: 218 ident: bb0575 article-title: Delivery of DNA vaccines: an overview on the use of biodegradable polymeric and magnetic nanoparticles publication-title: Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. – volume: 28 start-page: 482 year: 2007 end-page: 490 ident: bb0150 article-title: Immunogenicity of protein therapeutics publication-title: Trends Immunol. – volume: 110 start-page: 103 year: 2007 end-page: 111 ident: bb0060 article-title: Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients publication-title: Cancer – volume: 101 start-page: 946 year: 2012 end-page: 954 ident: bb0295 article-title: Protein instability and immunogenicity: roadblocks to clinical application of injectable protein delivery systems for sustained release publication-title: J. Pharm. Sci. – volume: 23 start-page: 9 year: 2007 end-page: 23 ident: bb0330 article-title: Streptokinase—the drug of choice for thrombolytic therapy publication-title: J. Thromb. Thrombolysis – volume: 122 start-page: 900 year: 1979 end-page: 905 ident: bb0485 article-title: Production of antibodies against phosphocholine, phosphatidylcholine, sphingomyelin, and lipid A by injection of liposomes containing lipid A publication-title: J. Immunol. – volume: 369 start-page: 411 year: 1999 end-page: 413 ident: bb0380 article-title: Immunostimulating effect of water-soluble fullerene derivatives–perspective adjuvants for a new generation of vaccine publication-title: Dokl. Akad. Nauk – volume: 133 start-page: 2525 year: 2011 end-page: 2534 ident: bb0390 article-title: Physical–chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles publication-title: J. Am. Chem. Soc. – volume: 151 start-page: 458 year: 2010 end-page: 465 ident: bb0580 article-title: Nanoparticles and the immune system publication-title: Endocrinology – volume: 6 start-page: 191 year: 2004 end-page: 202 ident: bb0345 article-title: Biochemical and immunological properties of cytokines conjugated to dendritic polymers publication-title: Biomed. Microdevices – volume: 40 start-page: 303 year: 1986 end-page: 314 ident: bb0035 article-title: Antibodies to liposomes, phospholipids and phosphate esters publication-title: Chem. Phys. Lipids – volume: 5 start-page: 487 year: 2008 end-page: 495 ident: bb0165 article-title: Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution publication-title: Mol. Pharm. – volume: 95 start-page: 403 year: 2004 end-page: 412 ident: bb0250 article-title: Effect of the physicochemical properties of initially injected liposomes on the clearance of subsequently injected PEGylated liposomes in mice publication-title: J. Control. Release – volume: 6 start-page: 1509 year: 2014 end-page: 1523 ident: bb0535 article-title: Strategic characterization of anti-drug antibody responses for the assessment of clinical relevance and impact publication-title: Bioanalysis – volume: 98 start-page: 1201 year: 2009 end-page: 1205 ident: bb0100 article-title: Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality publication-title: J. Pharm. Sci. – volume: 19 start-page: 1945 year: 2014 end-page: 1952 ident: bb0560 article-title: Potential induction of anti-PEG antibodies and complement activation toward PEGylated therapeutics publication-title: Drug Discov. Today – volume: 25 start-page: 1159 year: 2007 end-page: 1164 ident: bb0435 article-title: Exploiting lymphatic transport and complement activation in nanoparticle vaccines publication-title: Nat. Biotechnol. – volume: 283 start-page: 36031 year: 2008 end-page: 36038 ident: bb0570 article-title: Human anti-gold antibodies: biofunctionalization of gold nanoparticles and surfaces with anti-gold antibodies publication-title: J. Biol. Chem. – volume: 122 start-page: 349 year: 2007 end-page: 355 ident: bb0275 article-title: PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner publication-title: J. Control. Release – volume: 3 start-page: 165 year: 2006 end-page: 172 ident: bb0525 article-title: Immunogenicity issues in drug development publication-title: J. Immunotoxicol. – volume: 38 start-page: 602 year: 2010 end-page: 611 ident: bb0105 article-title: Meeting report on protein particles and immunogenicity of therapeutic proteins: filling in the gaps in risk evaluation and mitigation publication-title: Biologicals – volume: 90 start-page: 64 year: 2003 end-page: 70 ident: bb0335 article-title: Accelerated thrombolysis in a rabbit model of carotid artery thrombosis with liposome-encapsulated and microencapsulated streptokinase publication-title: Thromb. Haemost. – year: 2012 ident: bb0395 article-title: Janeway's Immunobiology Garland Science – volume: 98 start-page: 3218 year: 2009 end-page: 3238 ident: bb0085 article-title: Monoclonal antibody interactions with micro- and nanoparticles: adsorption, aggregation, and accelerated stress studies publication-title: J. Pharm. Sci. – start-page: 547 year: 2013 end-page: 580 ident: bb0155 article-title: Nanoparticles and antigenicity publication-title: Handbook of Immunological Properties of Engineered Nanomaterilas – volume: 98 start-page: 3167 year: 2009 end-page: 3181 ident: bb0540 article-title: Silicone oil- and agitation-induced aggregation of a monoclonal antibody in aqueous solution publication-title: J. Pharm. Sci. – volume: 115 start-page: 251 year: 2006 end-page: 258 ident: bb0260 article-title: Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection publication-title: J. Control. Release – volume: 104 start-page: 527 year: 2015 end-page: 535 ident: bb0325 article-title: Effects of syringe material and silicone oil lubrication on the stability of pharmaceutical proteins publication-title: J. Pharm. Sci. – volume: 105 start-page: 305 year: 2005 end-page: 317 ident: bb0255 article-title: Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes publication-title: J. Control. Release – volume: 30 start-page: 396 year: 2001 end-page: 402 ident: bb0545 article-title: Sensitive measurement of polyethylene glycol-modified proteins publication-title: Biotechniques – volume: 64 start-page: 11 year: 2010 end-page: 19 ident: bb0365 article-title: Root cause analysis of tungsten-induced protein aggregation in pre-filled syringes publication-title: PDA J. Pharm. Sci. Technol. – volume: 368 start-page: 320 year: 2013 end-page: 332 ident: bb0375 article-title: Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis publication-title: N. Engl. J. Med. – volume: 277 start-page: 30 year: 2014 end-page: 38 ident: bb0215 article-title: Generation, characterization and in vivo biological activity of two distinct monoclonal anti-PEG IgMs publication-title: Toxicol. Appl. Pharmacol. – volume: 94 start-page: 256 year: 2005 end-page: 274 ident: bb0135 article-title: Heterogeneous nucleation-controlled particulate formation of recombinant human platelet-activating factor acetylhydrolase in pharmaceutical formulation publication-title: J. Pharm. Sci. – volume: 23 start-page: 485 year: 2012 end-page: 499 ident: bb0500 article-title: Role of the methoxy group in immune responses to mPEG–protein conjugates publication-title: Bioconjug. Chem. – volume: 30 start-page: 53 year: 1996 end-page: 65 ident: bb0450 article-title: Preliminary biological evaluation of polyamidoamine (PAMAM) Starburst dendrimers publication-title: J. Biomed. Mater. Res. – volume: 354 start-page: 56 year: 2008 end-page: 62 ident: bb0245 article-title: Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes publication-title: Int. J. Pharm. – volume: 98 start-page: 94 year: 2009 end-page: 104 ident: bb0550 article-title: IgG particle formation during filling pump operation: a case study of heterogeneous nucleation on stainless steel nanoparticles publication-title: J. Pharm. Sci. – volume: 184 start-page: 1 year: 2014 end-page: 8 ident: bb0210 article-title: B cell-intrinsic toll-like receptor 7 is responsible for the enhanced anti-PEG IgM production following injection of siRNA-containing PEGylated lipoplex in mice publication-title: J. Control. Release – volume: 3 start-page: 1 year: 2011 end-page: 11 ident: bb0240 article-title: Anti-PEG IgM response against PEGylated liposomes in mice and rats publication-title: Pharmaceutics – volume: 16 start-page: 6139 year: 2010 end-page: 6149 ident: bb0360 article-title: Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine publication-title: Clin. Cancer Res. – volume: 97 start-page: 3753 year: 2008 end-page: 3764 ident: bb0430 article-title: Passive transfer of polyethylene glycol to liposomal-recombinant human FVIII enhances its efficacy in a murine model for hemophilia A publication-title: J. Pharm. Sci. – volume: 192 start-page: 261 year: 1989 end-page: 269 ident: bb0400 article-title: Thrombolysis using liposomal-encapsulated streptokinase: an in vitro study publication-title: Proc. Soc. Exp. Biol. Med. – volume: 24 start-page: 1720 year: 2002 end-page: 1740 ident: bb0475 article-title: Immunogenicity of therapeutic proteins: clinical implications and future prospects publication-title: Clin. Ther. – volume: 101 start-page: 2952 year: 2012 end-page: 2959 ident: bb0370 article-title: Particles shed from syringe filters and their effects on agitation-induced protein aggregation publication-title: J. Pharm. Sci. – volume: 307 start-page: 93 year: 2006 end-page: 102 ident: bb0410 article-title: Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles publication-title: Int. J. Pharm. – volume: 101 start-page: 187 year: 2012 ident: 10.1016/j.taap.2016.01.005_bb0555 article-title: Immunogenicity of recombinant human interferon beta interacting with particles of glass, metal, and polystyrene publication-title: J. Pharm. Sci. doi: 10.1002/jps.22744 – year: 2012 ident: 10.1016/j.taap.2016.01.005_bb0395 – volume: 100 start-page: 4953 year: 2011 ident: 10.1016/j.taap.2016.01.005_bb0195 article-title: Glass particles as an adjuvant: a model for adverse immunogenicity of therapeutic proteins publication-title: J. Pharm. Sci. doi: 10.1002/jps.22683 – volume: 94 start-page: 256 year: 2005 ident: 10.1016/j.taap.2016.01.005_bb0135 article-title: Heterogeneous nucleation-controlled particulate formation of recombinant human platelet-activating factor acetylhydrolase in pharmaceutical formulation publication-title: J. Pharm. Sci. doi: 10.1002/jps.20237 – volume: 76 start-page: 801 year: 2007 ident: 10.1016/j.taap.2016.01.005_bb0175 article-title: Gout: an update publication-title: Am. Fam. Physician – volume: 119 start-page: 236 year: 2007 ident: 10.1016/j.taap.2016.01.005_bb0565 article-title: Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes publication-title: J. Control. Release doi: 10.1016/j.jconrel.2007.02.010 – volume: 30 start-page: 53 year: 1996 ident: 10.1016/j.taap.2016.01.005_bb0450 article-title: Preliminary biological evaluation of polyamidoamine (PAMAM) Starburst dendrimers publication-title: J. Biomed. Mater. Res. doi: 10.1002/(SICI)1097-4636(199601)30:1<53::AID-JBM8>3.0.CO;2-Q – volume: 252 start-page: 3578 year: 1977 ident: 10.1016/j.taap.2016.01.005_bb0015 article-title: Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol publication-title: J. Biol. Chem. doi: 10.1016/S0021-9258(17)40291-2 – volume: 101 start-page: 946 year: 2012 ident: 10.1016/j.taap.2016.01.005_bb0295 article-title: Protein instability and immunogenicity: roadblocks to clinical application of injectable protein delivery systems for sustained release publication-title: J. Pharm. Sci. doi: 10.1002/jps.23018 – volume: 30 start-page: 985 year: 2013 ident: 10.1016/j.taap.2016.01.005_bb0460 article-title: Accelerated blood clearance of PEGylated PLGA nanoparticles following repeated injections: effects of polymer dose, PEG coating, and encapsulated anticancer drug publication-title: Pharm. Res. doi: 10.1007/s11095-012-0934-y – start-page: 547 year: 2013 ident: 10.1016/j.taap.2016.01.005_bb0155 article-title: Nanoparticles and antigenicity – volume: 61 start-page: 428 year: 2009 ident: 10.1016/j.taap.2016.01.005_bb0025 article-title: Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy publication-title: Adv. Drug Deliv. Rev. doi: 10.1016/j.addr.2009.03.009 – volume: 90 start-page: 64 year: 2003 ident: 10.1016/j.taap.2016.01.005_bb0335 article-title: Accelerated thrombolysis in a rabbit model of carotid artery thrombosis with liposome-encapsulated and microencapsulated streptokinase publication-title: Thromb. Haemost. doi: 10.1055/s-0037-1613600 – volume: 74 start-page: 36 year: 1984 ident: 10.1016/j.taap.2016.01.005_bb0445 article-title: Polyethylene glycol reactive antibodies in man: titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and in healthy blood donors publication-title: Int. Arch. Allergy Appl. Immunol. doi: 10.1159/000233512 – volume: 77 start-page: 1174 year: 1997 ident: 10.1016/j.taap.2016.01.005_bb0420 article-title: Streptokinase entrapment in interdigitation-fusion liposomes improves thrombolysis in an experimental rabbit model publication-title: Thromb. Haemost. doi: 10.1055/s-0038-1656133 – volume: 40 start-page: 303 year: 1986 ident: 10.1016/j.taap.2016.01.005_bb0035 article-title: Antibodies to liposomes, phospholipids and phosphate esters publication-title: Chem. Phys. Lipids doi: 10.1016/0009-3084(86)90075-7 – volume: 98 start-page: 94 year: 2009 ident: 10.1016/j.taap.2016.01.005_bb0550 article-title: IgG particle formation during filling pump operation: a case study of heterogeneous nucleation on stainless steel nanoparticles publication-title: J. Pharm. Sci. doi: 10.1002/jps.21419 – volume: 25 start-page: 1159 year: 2007 ident: 10.1016/j.taap.2016.01.005_bb0435 article-title: Exploiting lymphatic transport and complement activation in nanoparticle vaccines publication-title: Nat. Biotechnol. doi: 10.1038/nbt1332 – volume: 130 start-page: 1390 year: 1983 ident: 10.1016/j.taap.2016.01.005_bb0440 article-title: Antibodies reactive with liposomal phospholipids are produced during experimental Trypanosoma rhodesiense infections in rabbits publication-title: J. Immunol. doi: 10.4049/jimmunol.130.3.1390 – volume: 57 start-page: 236 year: 2014 ident: 10.1016/j.taap.2016.01.005_bb0465 article-title: Selectivity of binding of PEGs and PEG-like oligomers to anti-PEG antibodies induced by methoxyPEG-proteins publication-title: Mol. Immunol. doi: 10.1016/j.molimm.2013.07.014 – volume: 95 start-page: 403 year: 2004 ident: 10.1016/j.taap.2016.01.005_bb0250 article-title: Effect of the physicochemical properties of initially injected liposomes on the clearance of subsequently injected PEGylated liposomes in mice publication-title: J. Control. Release doi: 10.1016/j.jconrel.2003.12.011 – volume: 2 start-page: 205 year: 2010 ident: 10.1016/j.taap.2016.01.005_bb0575 article-title: Delivery of DNA vaccines: an overview on the use of biodegradable polymeric and magnetic nanoparticles publication-title: Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. doi: 10.1002/wnan.88 – volume: 137 start-page: 98 year: 2012 ident: 10.1016/j.taap.2016.01.005_bb0225 article-title: Production of monoclonal antibodies against fullerene C60 and development of a fullerene enzyme immunoassay publication-title: Analyst doi: 10.1039/C1AN15745K – volume: 6 start-page: 1870 year: 2006 ident: 10.1016/j.taap.2016.01.005_bb0065 article-title: Antibody molecules discriminate between crystalline facets of a gallium arsenide semiconductor publication-title: Nano Lett. doi: 10.1021/nl0607636 – volume: 60 start-page: 1651 year: 2008 ident: 10.1016/j.taap.2016.01.005_bb0140 article-title: Repeated injection of pegylated liposomal antitumour drugs induces the disappearance of the rapid distribution phase publication-title: J. Pharm. Pharmacol. doi: 10.1211/jpp.60.12.0011 – volume: 368 start-page: 320 year: 2013 ident: 10.1016/j.taap.2016.01.005_bb0375 article-title: Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1203166 – volume: 9 start-page: 38 year: 2011 ident: 10.1016/j.taap.2016.01.005_bb0385 article-title: Analysis and immunogenic potential of aggregates and particles: a practical approach, part 2 publication-title: BioProcess International – volume: 19 start-page: 1945 year: 2014 ident: 10.1016/j.taap.2016.01.005_bb0560 article-title: Potential induction of anti-PEG antibodies and complement activation toward PEGylated therapeutics publication-title: Drug Discov. Today doi: 10.1016/j.drudis.2014.08.015 – volume: 252 start-page: 3582 year: 1977 ident: 10.1016/j.taap.2016.01.005_bb0010 article-title: Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase publication-title: J. Biol. Chem. doi: 10.1016/S0021-9258(17)40292-4 – volume: 3 start-page: 165 year: 2006 ident: 10.1016/j.taap.2016.01.005_bb0525 article-title: Immunogenicity issues in drug development publication-title: J. Immunotoxicol. doi: 10.1080/15476910600908852 – volume: 16 start-page: 6139 year: 2010 ident: 10.1016/j.taap.2016.01.005_bb0360 article-title: Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-10-0978 – volume: 28 start-page: 482 year: 2007 ident: 10.1016/j.taap.2016.01.005_bb0150 article-title: Immunogenicity of protein therapeutics publication-title: Trends Immunol. doi: 10.1016/j.it.2007.07.011 – volume: 98 start-page: 3218 year: 2009 ident: 10.1016/j.taap.2016.01.005_bb0085 article-title: Monoclonal antibody interactions with micro- and nanoparticles: adsorption, aggregation, and accelerated stress studies publication-title: J. Pharm. Sci. doi: 10.1002/jps.21768 – volume: 16 start-page: 499 year: 2014 ident: 10.1016/j.taap.2016.01.005_bb0415 article-title: New FDA draft guidance on immunogenicity publication-title: AAPS J. doi: 10.1208/s12248-014-9587-6 – volume: 262 start-page: 1448 year: 1993 ident: 10.1016/j.taap.2016.01.005_bb0070 article-title: The influence of antigen organization on B cell responsiveness publication-title: Science doi: 10.1126/science.8248784 – volume: 115 start-page: 251 year: 2006 ident: 10.1016/j.taap.2016.01.005_bb0260 article-title: Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection publication-title: J. Control. Release doi: 10.1016/j.jconrel.2006.08.017 – volume: 5 start-page: 487 year: 2008 ident: 10.1016/j.taap.2016.01.005_bb0165 article-title: Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution publication-title: Mol. Pharm. doi: 10.1021/mp800032f – volume: 21 start-page: 897 year: 2004 ident: 10.1016/j.taap.2016.01.005_bb0235 article-title: Structure–immunogenicity relationships of therapeutic proteins publication-title: Pharm. Res. doi: 10.1023/B:PHAM.0000029275.41323.a6 – volume: 362 start-page: 197 year: 2008 ident: 10.1016/j.taap.2016.01.005_bb0315 article-title: Particle size-dependent triggering of accelerated blood clearance phenomenon publication-title: Int. J. Pharm. doi: 10.1016/j.ijpharm.2008.06.004 – volume: 370 start-page: 261 year: 2000 ident: 10.1016/j.taap.2016.01.005_bb0045 article-title: Immunogenic and allergenic properties of fulleren conjugates with aminoacids and proteins publication-title: Dokl. Biochem. – volume: 97 start-page: 3753 year: 2008 ident: 10.1016/j.taap.2016.01.005_bb0430 article-title: Passive transfer of polyethylene glycol to liposomal-recombinant human FVIII enhances its efficacy in a murine model for hemophilia A publication-title: J. Pharm. Sci. doi: 10.1002/jps.21266 – volume: 6 start-page: 393 year: 2001 ident: 10.1016/j.taap.2016.01.005_bb0180 article-title: Glass vials for small volume parenterals: influence of drug and manufacturing processes on glass delamination publication-title: Pharm. Dev. Technol. doi: 10.1081/PDT-100002248 – volume: 184 start-page: 1 year: 2014 ident: 10.1016/j.taap.2016.01.005_bb0210 article-title: B cell-intrinsic toll-like receptor 7 is responsible for the enhanced anti-PEG IgM production following injection of siRNA-containing PEGylated lipoplex in mice publication-title: J. Control. Release doi: 10.1016/j.jconrel.2014.04.003 – volume: 23 start-page: 485 year: 2012 ident: 10.1016/j.taap.2016.01.005_bb0500 article-title: Role of the methoxy group in immune responses to mPEG–protein conjugates publication-title: Bioconjug. Chem. doi: 10.1021/bc200551b – volume: 100 start-page: 5069 year: 2011 ident: 10.1016/j.taap.2016.01.005_bb0305 article-title: Differences in colloidal structure of PEGylated nanomaterials dictate the likelihood of accelerated blood clearance publication-title: J. Pharm. Sci. doi: 10.1002/jps.22682 – volume: 128 start-page: 1603 year: 1982 ident: 10.1016/j.taap.2016.01.005_bb0075 article-title: Antibodies against liposomes in normal and immune-defective mice publication-title: J. Immunol. doi: 10.4049/jimmunol.128.4.1603 – volume: 312 start-page: 1020 year: 2005 ident: 10.1016/j.taap.2016.01.005_bb0495 article-title: Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic acid publication-title: J. Pharmacol. Exp. Ther. doi: 10.1124/jpet.104.078113 – volume: 98 start-page: 3167 year: 2009 ident: 10.1016/j.taap.2016.01.005_bb0540 article-title: Silicone oil- and agitation-induced aggregation of a monoclonal antibody in aqueous solution publication-title: J. Pharm. Sci. doi: 10.1002/jps.21719 – volume: 28 start-page: 309 year: 2002 ident: 10.1016/j.taap.2016.01.005_bb0310 article-title: Hemophilia A—from basic science to clinical practice publication-title: Semin. Thromb. Hemost. doi: 10.1055/s-2002-32667 – volume: 58 start-page: 1491 year: 2006 ident: 10.1016/j.taap.2016.01.005_bb0020 article-title: Investigations on the toxicological profile of functionalized fifth-generation poly (propylene imine) dendrimer publication-title: J. Pharm. Pharmacol. doi: 10.1211/jpp.58.11.0010 – volume: 98 start-page: 4695 year: 2009 ident: 10.1016/j.taap.2016.01.005_bb0290 article-title: Tungsten-induced protein aggregation: solution behavior publication-title: J. Pharm. Sci. doi: 10.1002/jps.21778 – volume: 122 start-page: 900 year: 1979 ident: 10.1016/j.taap.2016.01.005_bb0485 article-title: Production of antibodies against phosphocholine, phosphatidylcholine, sphingomyelin, and lipid A by injection of liposomes containing lipid A publication-title: J. Immunol. doi: 10.4049/jimmunol.122.3.900 – volume: 6 start-page: 1509 year: 2014 ident: 10.1016/j.taap.2016.01.005_bb0535 article-title: Strategic characterization of anti-drug antibody responses for the assessment of clinical relevance and impact publication-title: Bioanalysis doi: 10.4155/bio.14.114 – volume: 3 start-page: 53 year: 2001 ident: 10.1016/j.taap.2016.01.005_bb0340 article-title: Recognition properties of antibodies to PAMAM dendrimers and their use in immune detection of dendrimers publication-title: Biomed. Microdevices doi: 10.1023/A:1011429404950 – volume: 30 start-page: 1729 year: 2013 ident: 10.1016/j.taap.2016.01.005_bb0480 article-title: The immunogenicity of polyethylene glycol: facts and fiction publication-title: Pharm. Res. doi: 10.1007/s11095-013-1067-7 – volume: 95 start-page: 10809 year: 1998 ident: 10.1016/j.taap.2016.01.005_bb0125 article-title: Antigenicity of fullerenes: antibodies specific for fullerenes and their characteristics publication-title: Proc. Natl. Acad. Sci. U. S. A. doi: 10.1073/pnas.95.18.10809 – volume: 192 start-page: 261 year: 1989 ident: 10.1016/j.taap.2016.01.005_bb0400 article-title: Thrombolysis using liposomal-encapsulated streptokinase: an in vitro study publication-title: Proc. Soc. Exp. Biol. Med. doi: 10.3181/00379727-192-42995 – volume: 101 start-page: 2952 year: 2012 ident: 10.1016/j.taap.2016.01.005_bb0370 article-title: Particles shed from syringe filters and their effects on agitation-induced protein aggregation publication-title: J. Pharm. Sci. doi: 10.1002/jps.23225 – volume: 31 start-page: 53 year: 2010 ident: 10.1016/j.taap.2016.01.005_bb0470 article-title: Immunological mechanism underlying the immune response to recombinant human protein therapeutics publication-title: Trends Pharmacol. Sci. doi: 10.1016/j.tips.2009.11.001 – volume: 90 start-page: 6385 year: 1993 ident: 10.1016/j.taap.2016.01.005_bb0080 article-title: Direct selection of antibodies that coordinate metals from semisynthetic combinatorial libraries publication-title: Proc. Natl. Acad. Sci. U. S. A. doi: 10.1073/pnas.90.14.6385 – volume: 30 start-page: 396 year: 2001 ident: 10.1016/j.taap.2016.01.005_bb0545 article-title: Sensitive measurement of polyethylene glycol-modified proteins publication-title: Biotechniques doi: 10.2144/01302rr03 – volume: 12 start-page: 342 year: 1984 ident: 10.1016/j.taap.2016.01.005_bb0030 article-title: Natural antibodies against phospholipids and liposomes in humans publication-title: Biochem. Soc. Trans. doi: 10.1042/bst0120342 – volume: 292 start-page: 1071 year: 2000 ident: 10.1016/j.taap.2016.01.005_bb0145 article-title: Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes publication-title: J. Pharmacol. Exp. Ther. doi: 10.1016/S0022-3565(24)35391-1 – volume: 2 start-page: 469 year: 2007 ident: 10.1016/j.taap.2016.01.005_bb0160 article-title: Immunological properties of engineered nanomaterials publication-title: Nat. Nanotechnol. doi: 10.1038/nnano.2007.223 – volume: 39 start-page: 100 year: 2011 ident: 10.1016/j.taap.2016.01.005_bb0095 article-title: Taking immunogenicity assessment of therapeutic proteins to the next level publication-title: Biologicals doi: 10.1016/j.biologicals.2011.01.006 – volume: 105 start-page: 305 year: 2005 ident: 10.1016/j.taap.2016.01.005_bb0255 article-title: Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes publication-title: J. Control. Release doi: 10.1016/j.jconrel.2005.04.003 – volume: 346 start-page: 1584 year: 2002 ident: 10.1016/j.taap.2016.01.005_bb0205 article-title: Pure red-cell aplasia and recombinant erythropoietin publication-title: N. Engl. J. Med. doi: 10.1056/NEJM200205163462015 – volume: 283 start-page: 36031 year: 2008 ident: 10.1016/j.taap.2016.01.005_bb0570 article-title: Human anti-gold antibodies: biofunctionalization of gold nanoparticles and surfaces with anti-gold antibodies publication-title: J. Biol. Chem. doi: 10.1074/jbc.M805547200 – volume: 97 start-page: 12193 year: 2000 ident: 10.1016/j.taap.2016.01.005_bb0090 article-title: X-ray crystal structure of an anti-Buckminsterfullerene antibody fab fragment: biomolecular recognition of C(60) publication-title: Proc. Natl. Acad. Sci. U. S. A. doi: 10.1073/pnas.210396197 – volume: 20 start-page: 1903 year: 2003 ident: 10.1016/j.taap.2016.01.005_bb0230 article-title: Micelle-associated protein in epoetin formulations: a risk factor for immunogenicity? publication-title: Pharm. Res. doi: 10.1023/B:PHAM.0000008034.61317.02 – volume: 218 start-page: 725 year: 2013 ident: 10.1016/j.taap.2016.01.005_bb0505 article-title: Transport of PEGylated liposomes from the splenic marginal zone to the follicle in the induction phase of the accelerated blood clearance phenomenon publication-title: Immunobiology doi: 10.1016/j.imbio.2012.08.274 – volume: 306 start-page: 1058 year: 2003 ident: 10.1016/j.taap.2016.01.005_bb0120 article-title: Multiple injections of pegylated liposomal Doxorubicin: pharmacokinetics and therapeutic activity publication-title: J. Pharmacol. Exp. Ther. doi: 10.1124/jpet.103.053413 – volume: 1 start-page: 465 year: 2001 ident: 10.1016/j.taap.2016.01.005_bb0185 article-title: Binding of an anti-fullerene IgG monoclonal antibody to single wall carbon nanotubes publication-title: Nano Lett. doi: 10.1021/nl015570r – volume: 6 start-page: 191 year: 2004 ident: 10.1016/j.taap.2016.01.005_bb0345 article-title: Biochemical and immunological properties of cytokines conjugated to dendritic polymers publication-title: Biomed. Microdevices doi: 10.1023/B:BMMD.0000042048.18186.ff – volume: 41 start-page: 29S year: 2001 ident: 10.1016/j.taap.2016.01.005_bb0350 article-title: Normal donor sera can contain antibodies to polyethylene glycol (PEG) publication-title: Transfusion – volume: 101 start-page: 3864 year: 2012 ident: 10.1016/j.taap.2016.01.005_bb0355 article-title: Accelerated blood clearance of pegylated liposomal topotecan: influence of polyethylene glycol grafting density and animal species publication-title: J. Pharm. Sci. doi: 10.1002/jps.23254 – volume: 115 start-page: 243 year: 2006 ident: 10.1016/j.taap.2016.01.005_bb0265 article-title: Spleen plays an important role in the induction of accelerated blood clearance of PEGylated liposomes publication-title: J. Control. Release doi: 10.1016/j.jconrel.2006.08.001 – volume: 9 start-page: 1319 year: 2012 ident: 10.1016/j.taap.2016.01.005_bb0200 article-title: Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents publication-title: Expert. Opin. Drug Deliv. doi: 10.1517/17425247.2012.720969 – volume: 98 start-page: 1201 year: 2009 ident: 10.1016/j.taap.2016.01.005_bb0100 article-title: Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality publication-title: J. Pharm. Sci. doi: 10.1002/jps.21530 – volume: 10 start-page: 520 year: 1999 ident: 10.1016/j.taap.2016.01.005_bb0130 article-title: Accelerated clearance of polyethylene glycol-modified proteins by anti-polyethylene glycol IgM publication-title: Bioconjug. Chem. doi: 10.1021/bc980143z – volume: 151 start-page: 458 year: 2010 ident: 10.1016/j.taap.2016.01.005_bb0580 article-title: Nanoparticles and the immune system publication-title: Endocrinology doi: 10.1210/en.2009-1082 – volume: 11 start-page: 2700 year: 2010 ident: 10.1016/j.taap.2016.01.005_bb0285 article-title: Evasion of the accelerated blood clearance phenomenon by coating of nanoparticles with various hydrophilic polymers publication-title: Biomacromolecules doi: 10.1021/bm100754e – volume: 29 start-page: 551 year: 2008 ident: 10.1016/j.taap.2016.01.005_bb0055 article-title: Complement activation on surfaces modified with ethylene glycol units publication-title: Biomaterials doi: 10.1016/j.biomaterials.2007.10.015 – volume: 173 start-page: 3148 year: 2004 ident: 10.1016/j.taap.2016.01.005_bb0190 article-title: Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors publication-title: J. Immunol. doi: 10.4049/jimmunol.173.5.3148 – volume: 24 start-page: 1720 year: 2002 ident: 10.1016/j.taap.2016.01.005_bb0475 article-title: Immunogenicity of therapeutic proteins: clinical implications and future prospects publication-title: Clin. Ther. doi: 10.1016/S0149-2918(02)80075-3 – volume: 133 start-page: 2525 year: 2011 ident: 10.1016/j.taap.2016.01.005_bb0390 article-title: Physical–chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles publication-title: J. Am. Chem. Soc. doi: 10.1021/ja107583h – volume: 104 start-page: 527 year: 2015 ident: 10.1016/j.taap.2016.01.005_bb0325 article-title: Effects of syringe material and silicone oil lubrication on the stability of pharmaceutical proteins publication-title: J. Pharm. Sci. doi: 10.1002/jps.24184 – volume: 112 start-page: 3 year: 2003 ident: 10.1016/j.taap.2016.01.005_bb0110 article-title: An overview of scientific and regulatory issues for the immunogenicity of biological products publication-title: Dev. Biol. (Basel) – volume: 3 start-page: 1 year: 2011 ident: 10.1016/j.taap.2016.01.005_bb0240 article-title: Anti-PEG IgM response against PEGylated liposomes in mice and rats publication-title: Pharmaceutics doi: 10.3390/pharmaceutics3010001 – volume: 66 start-page: 875 year: 1990 ident: 10.1016/j.taap.2016.01.005_bb0405 article-title: Accelerated thrombolysis and reperfusion in a canine model of myocardial infarction by liposomal encapsulation of streptokinase publication-title: Circ. Res. doi: 10.1161/01.RES.66.3.875 – volume: 122 start-page: 349 year: 2007 ident: 10.1016/j.taap.2016.01.005_bb0275 article-title: PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner publication-title: J. Control. Release doi: 10.1016/j.jconrel.2007.05.015 – volume: 64 start-page: 11 year: 2010 ident: 10.1016/j.taap.2016.01.005_bb0365 article-title: Root cause analysis of tungsten-induced protein aggregation in pre-filled syringes publication-title: PDA J. Pharm. Sci. Technol. – volume: 277 start-page: 30 year: 2014 ident: 10.1016/j.taap.2016.01.005_bb0215 article-title: Generation, characterization and in vivo biological activity of two distinct monoclonal anti-PEG IgMs publication-title: Toxicol. Appl. Pharmacol. doi: 10.1016/j.taap.2014.03.002 – volume: 38 start-page: 602 year: 2010 ident: 10.1016/j.taap.2016.01.005_bb0105 article-title: Meeting report on protein particles and immunogenicity of therapeutic proteins: filling in the gaps in risk evaluation and mitigation publication-title: Biologicals doi: 10.1016/j.biologicals.2010.07.002 – volume: 13 start-page: 328 year: 2006 ident: 10.1016/j.taap.2016.01.005_bb0300 article-title: Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes publication-title: Mol. Ther. doi: 10.1016/j.ymthe.2005.09.014 – volume: 126 start-page: 162 year: 2008 ident: 10.1016/j.taap.2016.01.005_bb0280 article-title: The contribution of phagocytic activity of liver macrophages to the accelerated blood clearance (ABC) phenomenon of PEGylated liposomes in rats publication-title: J. Control. Release doi: 10.1016/j.jconrel.2007.11.009 – volume: 392 start-page: 218 year: 2010 ident: 10.1016/j.taap.2016.01.005_bb0320 article-title: T cell-independent B cell response is responsible for ABC phenomenon induced by repeated injection of PEGylated liposomes publication-title: Int. J. Pharm. doi: 10.1016/j.ijpharm.2010.03.022 – volume: 29 start-page: 1454 year: 2012 ident: 10.1016/j.taap.2016.01.005_bb0490 article-title: Tungsten-induced denaturation and aggregation of epoetin alfa during primary packaging as a cause of immunogenicity publication-title: Pharm. Res. doi: 10.1007/s11095-011-0621-4 – volume: 97 start-page: 1386 year: 2008 ident: 10.1016/j.taap.2016.01.005_bb0425 article-title: Phosphatidylserine containing liposomes reduce immunogenicity of recombinant human factor VIII (rFVIII) in a murine model of hemophilia A publication-title: J. Pharm. Sci. doi: 10.1002/jps.21102 – volume: 13 start-page: 592 year: 2013 ident: 10.1016/j.taap.2016.01.005_bb0510 article-title: Applications of nanotechnology for immunology publication-title: Nat. Rev. Immunol. doi: 10.1038/nri3488 – volume: 110 start-page: 103 year: 2007 ident: 10.1016/j.taap.2016.01.005_bb0060 article-title: Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients publication-title: Cancer doi: 10.1002/cncr.22739 – volume: 127 start-page: 40 year: 1996 ident: 10.1016/j.taap.2016.01.005_bb0040 article-title: Immunization with cholesterol-rich liposomes induces anti-cholesterol antibodies and reduces diet-induced hypercholesterolemia and plaque formation publication-title: J. Lab. Clin. Med. doi: 10.1016/S0022-2143(96)90164-X – volume: 172 start-page: 38 year: 2013 ident: 10.1016/j.taap.2016.01.005_bb0005 article-title: The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage publication-title: J. Control. Release doi: 10.1016/j.jconrel.2013.07.026 – start-page: 86 year: 2004 ident: 10.1016/j.taap.2016.01.005_bb0170 article-title: Immunogenic properties of the colloidal gold publication-title: Izv. Akad. Nauk Ser. Biol. – volume: 38 start-page: 417 year: 2015 ident: 10.1016/j.taap.2016.01.005_bb0220 article-title: Relationship between the concentration of anti-polyethylene glycol (PEG) immunoglobulin M (IgM) and the intensity of the accelerated blood clearance (ABC) phenomenon against PEGylated liposomes in mice publication-title: Biol. Pharm. Bull. doi: 10.1248/bpb.b14-00653 – volume: 354 start-page: 56 year: 2008 ident: 10.1016/j.taap.2016.01.005_bb0245 article-title: Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes publication-title: Int. J. Pharm. doi: 10.1016/j.ijpharm.2007.11.005 – volume: 142 start-page: 160 year: 2010 ident: 10.1016/j.taap.2016.01.005_bb0530 article-title: CpG motifs in pDNA-sequences increase anti-PEG IgM production induced by PEG-coated pDNA-lipoplexes publication-title: J. Control. Release doi: 10.1016/j.jconrel.2009.10.017 – volume: 112 start-page: 15 year: 2003 ident: 10.1016/j.taap.2016.01.005_bb0455 article-title: Immunogenicity of biological therapeutics: a hierarchy of concerns publication-title: Dev. Biol. (Basel) – volume: 307 start-page: 93 year: 2006 ident: 10.1016/j.taap.2016.01.005_bb0410 article-title: Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles publication-title: Int. J. Pharm. doi: 10.1016/j.ijpharm.2005.10.010 – volume: 370 start-page: 4 year: 2000 ident: 10.1016/j.taap.2016.01.005_bb0050 article-title: Immunogenic and allergenic properties of fulleren conjugates with aminoacids and proteins publication-title: Dokl. Biochem. – volume: 112 start-page: 15 year: 2006 ident: 10.1016/j.taap.2016.01.005_bb0270 article-title: Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes publication-title: J. Control. Release doi: 10.1016/j.jconrel.2006.01.005 – volume: 369 start-page: 411 year: 1999 ident: 10.1016/j.taap.2016.01.005_bb0380 article-title: Immunostimulating effect of water-soluble fullerene derivatives–perspective adjuvants for a new generation of vaccine publication-title: Dokl. Akad. Nauk – volume: 23 start-page: 9 year: 2007 ident: 10.1016/j.taap.2016.01.005_bb0330 article-title: Streptokinase—the drug of choice for thrombolytic therapy publication-title: J. Thromb. Thrombolysis doi: 10.1007/s11239-006-9011-x |
| SSID | ssj0009441 |
| Score | 2.538883 |
| SecondaryResourceType | review_article |
| Snippet | Nanoparticle immunogenicity and antigenicity have been under investigation for many years. During the past decade, significant progress has been made in... |
| SourceID | pubmedcentral osti proquest pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 70 |
| SubjectTerms | 60 APPLIED LIFE SCIENCES Adjuvants, Immunologic - administration & dosage Adjuvants, Immunologic - toxicity ANAPHYLAXIS Animals ANTIBODIES Antibody ANTIBODY FORMATION Antigenic Modulation - drug effects Antigenic Modulation - immunology Antigenicity BIOTECHNOLOGY CARRIERS Comprehension Cytokines Drug Carriers - administration & dosage Drug Carriers - toxicity DRUG DELIVERY Drug Delivery Systems - adverse effects Drug Delivery Systems - methods ENGINEERS Forecasting Humans Immunity, Cellular - drug effects Immunity, Cellular - immunology Immunogenetic Phenomena - drug effects Immunogenetic Phenomena - immunology Immunogenicity LYMPHOKINES NANOMATERIALS NANOPARTICLES Nanostructures - administration & dosage Nanostructures - toxicity PARTICULATES Phagocytosis Preclinical REVIEWS |
| Title | Understanding the immunogenicity and antigenicity of nanomaterials: Past, present and future |
| URI | https://dx.doi.org/10.1016/j.taap.2016.01.005 https://www.ncbi.nlm.nih.gov/pubmed/26773813 https://www.proquest.com/docview/1777075683 https://www.proquest.com/docview/1785245142 https://www.osti.gov/biblio/22689167 https://pubmed.ncbi.nlm.nih.gov/PMC4811736 |
| Volume | 299 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Pa9swFBYlvQzGWLtf2bqiwuhl8WrZT5a9Wykr6cZKDg3kMBCyLFOPYYfFPfSyv33vWXbSjJLDDj7Y0jP68SR9st_3ibEPVsUFolqJs1_sAsigDIxxSeAgKU0JxsqEuMPfr5PpHL4u5GKPXQxcGAqr7Od-P6d3s3X_5KxvzbNlVRHHF0iZZiFINQpRAjHYQZGXf_qzCfPIAPypeYDbZszdE2d8jFdrDGlWiqST7qQj7B5fnEYNjrfHMOi_oZQP1qbL5-xZDyr5uS_3Adtz9SE7nXlV6vsJv9mQrFYTfspnG73q-0P21H-6456R9IL9mD8kvHBEiLwiFkmDvlZZRO0cU_Bqq_WDpuS1qRtEv96hP_OZWbUTvvTkps7Aq5e8ZPPLLzcX06A_hCGwMo3awMSQmdI5Z2OVZQXuLqI0d6ktQ1DW5lmJkMHIDseEmVFlJGyU21Q43DrK2ITxKzaqm9q9YRyEhchKiBwUmCZzh68uVGEgNK40aszE0Pra9grldFDGLz2Eov3U1GOaekyHQmOPjdnHtc3S63PszC2HTtVbXqZxAdlpd0QeQDYkrWspBgmNELqmCK-x4CeDZ2gcnfTLxdSuuVtpoZRCUJak8a482KaAwDUas9fem9ZViRKlEFOhtdrys3UGUgffTqmr204lHIhCHCdv_7PK79gTuqNACSGP2Kj9fefeI_5q8-NugB2z_fOrb9PrvwLNMgQ |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Pb9MwFLZGOYA0oTF-rLCBkdAuNFt-PMfJbtPEVGCbemilHpAsx3FEEEoqmh124W_nvThpVzT1wCGX2C-K7Wf7c_K-7zH20cgoR1QrcPWLrAcpFJ7WNvYsxIUuQBsRE3f4-iYez-DrXMx32EXPhaGwym7td2t6u1p3d0673jxdlCVxfIGUaeYBqUYhSnjEHgNOX0pjcPJnHeeRAri0eYDnZqzeMWdckFejNYlWBnGr3Uk57B7enQY1TriHQOi_sZT3NqfLPfasQ5X83L34c7Zjq312PHGy1HcjPl2zrJYjfswna8Hqu322677dcUdJesG-z-4zXjhCRF4SjaRGZysNwnaOJXg15epGXfBKVzXCX-fRZ3yil82ILxy7qTVw8iUv2ezy8_Ri7HVZGDwjkrDxdASpLqy1JpJpmuPxIkwym5jCB2lMlhaIGbRogYyfalmEgQkzkwQWz44i0n70ig2qurIHjENgIDQCQgs5lonM4qNzmWvwtS20HLKg731lOolyypTxS_WxaD8VjZiiEVN-oHDEhuzTymbhBDq21hb9oKoNN1O4g2y1OyQPIBvS1jUUhIRGiF0TxNf44h96z1A4Pemfi65sfbtUgZQSUVmcRNvqYJ8CItdwyF47b1o1JYylRFCF1nLDz1YVSB58s6Qqf7Qy4UAc4ih-859Nfs-ejKfXV-rqy823t-wplVDURCAO2aD5fWuPEIw12bt2sv0FsTgzkg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Understanding+the+immunogenicity+and+antigenicity+of+nanomaterials%3A+Past%2C+present+and+future&rft.jtitle=Toxicology+and+applied+pharmacology&rft.au=Ilinskaya%2C+Anna+N.&rft.au=Dobrovolskaia%2C+Marina+A.&rft.date=2016-05-15&rft.pub=Elsevier+Inc&rft.issn=0041-008X&rft.eissn=1096-0333&rft.volume=299&rft.spage=70&rft.epage=77&rft_id=info:doi/10.1016%2Fj.taap.2016.01.005&rft.externalDocID=S0041008X16300059 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0041-008X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0041-008X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0041-008X&client=summon |